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Abstract  
Advances in biology and physics have allowed increased precision and accuracy in 
radiotherapy (RT) in order to maximize tumor damage and to minimize lesions in the 
dose limiting adjacent normal tissues. The spinal cord is the most critical organ at risk 
(OAR). Radiation myelopathy is one of the most devastating complications of clinical 
radiotherapy resulting in severe and irreversible morbidity. Assessment of the impact of 
dose and fractionation schemes on tissue tolerance has been a major area of research 
in radiation oncology. As a result of greater accuracy and effectiveness of cancer 
treatment, patient survival rates increase, and radiation oncologists are frequently faced 
with the problem of treatment of local recurrence or second tumors located within or 
close to previously treated sites. Initial dose influences different time intervals from tissue 
tolerance to re-irradiation as well as conditioning the recovery of radiation damage in the 
first treatment. It is possible to administer a higher dose in the re-irradiation if smaller 
doses were used at the first treatment and if the intervals between treatments were 
longer. Radiation myelopathy is a rare late toxicity effect in the modern era of 3-
dimensional conformal conventionally fractionated RT. This devastating late effect has 
re-emerged as a direct result of SBRT practice, where high-dose radiation is delivered 
adjacent to the spinal cord to be spared. A comprehensive search was performed 
including relevant articles referring to “spinal cord”, “re-irradiation” and “myelopathy”.  
The biologically effective dose (BED) was calculated and the results are discussed 
considering radiobiological mechanisms. 
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Resumo 
Avanços na biologia e na física permitiram uma maior precisão e exatidão em 
radioterapia (RT), de modo a maximizar o dano tumoral e minimizar as lesões nos 
tecidos normais adjacentes, que limitam a dose. A medula espinal é denominada como 
o órgão mais crítico em risco (OAR – organ at risk). A mielopatia por radiação é uma 
das complicações mais devastadoras da radioterapia clínica, resultando em morbidade 
grave e irreversível. A avaliação do impacto dos esquemas de dose e fracionamento, na 
tolerância tecidual, tem sido uma das principais áreas de pesquisa em oncologia da 
radiação. Como resultado de uma maior precisão e eficácia do tratamento oncológico, 
as taxas de sobrevivência do paciente aumentam e os oncologistas de radiação são, 
frequentemente, confrontados com o problema do tratamento de recidiva local ou de 
segundos tumores localizados dentro ou próximos de locais previamente tratados. A 
dose inicial influencia diferentes intervalos de tempo, desde a tolerância do tecido à re-
irradiação, bem como, condiciona a recuperação do dano por radiação no primeiro 
tratamento. É possível administrar uma dose maior na re-irradiação se doses menores 
forem usadas no primeiro tratamento e se o intervalo de tempo entre o primeiro 
tratamento e a re-irradiação for mais longo. A mielopatia por radiação é um raro efeito 
de toxicidade tardia na era moderna da RT conformacional tridimensional convencional 
(3D- CRT). Este devastador efeito tardio ressurgiu como um resultado direto da prática 
de SBRT, onde a radiação de alta dose é administrada junto à medula espinal, que terá 
de ser poupada. Uma pesquisa abrangente foi realizada, incluindo artigos relevantes 
referentes a “medula espinal”, “re-irradiação” e “mielopatia”. A dose biologicamente 
efetiva (BED) foi calculada e os resultados são discutidos considerando os mecanismos 
radiobiológicos.  
 
Palavras-chave: Medula espinal, Radiobiologia, Re-irradiação, Tolerância.  
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Terms and Definitions 
The glossary of terms and definitions has been adapted from: the book "Radiobiology for the Radiologist", the Council 
Directive 2013/59/EURATOM of 5 December 2013, the International Atomic Energy Agency (IAEA) TRS-398 and the 
online dictionary “The Free Dictionary” [1, 2, 3, 4]. This glossary has specific terms used in radiotherapy, radiobiology, 
radiological quantities and some clinical terms. 
 
Absorbed dose – Measure of the energy imparted per 
unit mass by ionizing radiation to matter at a specific 
point. The SI unit of absorbed dose is joule per kilogram 
(J/kg). The denomination of this unit is gray (Gy). The 
previously used unit of absorbed dose, the rad, was 
defined to be an energy absorption of 100 erg/g. Thus, 
1 Gy = 100 rad. 
Absorption – Way in which the energy of a photon is 
taken up by matter, typically the electrons of an atom. 
Removal of x-rays from a beam. 
Accelerated fractionation – The treatment schedule, 
in this case, exceeds the equivalent of 10Gy per week, 
in fractions of 2 Gy. 
Acute hypoxia – Tumor region characterized by low 
oxygen concentration associated with changes in blood 
flow through the blood vessels may also be called 
perfusion limited hypoxia.   
Adjuvant therapy – Type of treatment to combat 
cancer, used in addition to primary therapy. Usually, 
radiotherapy is used as an adjuvant for surgery or 
chemotherapy. 
ALARA (as low as reasonably achievable) – Principle 
adopted to limit the dose of radiation to patients 
exposed to levels as low as reasonably possible, 
considering economic and social factors. 
Angiogenesis – Denomination for the process of 
formation of new blood vessels. 
Anterior – The ventral portion of a structure. 
Apoptosis – A mode of rapid cell death after irradiation 
in which the cell nucleus displays characteristic densely 
staining globules and at least some of the DNA is 
subsequently broken down into internucleosomal units. 
Bone marrow – The soft, organic, sponge like material 
in the cavities of bones; called also medulla ossium. 
Cancer – Characterized by uncontrolled growth of the 
cells in the human body and the ability of these cells to 
migrate from the original site and spread to distant sites. 
If the spread is not controlled, cancer can result in 
death. 
Cdks (cyclin-dependent kinases) – Proteins that 
complex with their cyclin regulatory subunits to 
phosphorylate proteins necessary for progression 
through the cell cycle. 
Cell cycle checkpoint – Mechanism of control that acts 
to verify if each phase of the cell cycle was completed 
correctly before progression to the next phase. 
Cells – Cells are the structural and functional units of 
living organisms. Each cell plays a specialized role in 
the body. Groups of cells are arranged together to form 
tissues. Tissues are organized to form organs in the 
body. 
Central nervous system (CNS) – The portion of the 
nervous system consisting of the brain and spinal cord. 
Dose – General term for the quantity of radiation. 
xxii 
 
Dose limit – Limit on dose that is applied for exposure 
of individuals to prevent the occurrence of deterministic 
effects and to limit the probability of stochastic effects. 
Dose rate – Radiation dose delivered per unit time and 
measured, for example, in grays per hour. 
ED50 (effect dose 50%) – Dose that produces the 
desired effect in 50 per cent of a population. 
Effective dose – (E) is the sum of the weighted 
equivalent doses in all the tissues and organs of the 
body from internal and external exposure. The unit for 
equivalent dose is the sievert (Sv). 
Equivalent dose – (HT) is the absorbed dose, in tissue 
or organ (T) weighted for the type and quality of 
radiation (R). The unit for equivalent dose is the sievert 
(Sv). 
Fractionation – The daily dose of radiation based on 
the total dose divided into several daily treatments. 
Free radical – A fragment of an atom or molecule that 
contains an unpaired electron, which, therefore, make it 
very reactive. 
Function subunits (FSU’s) – Many tissues can be 
thought of as consisting of discrete FSUs. These may 
be arranged in series as in the spinal cord, or in parallel 
as in the kidney. 
Gray (Gy) – The special name for the SI unit of 
absorbed dose, kerma, and specifi c energy imparted 
equal to 1 J/kg. The previous unit of absorbed dose, rad, 
has been replaced by the gray. One gray equals 100 
rad. 
Grey matter – Part of the central nervous system 
consisting mainly of nerve cell bodies. The grey matter 
of the brain includes the outer layer (the cortex) and 
several centrally placed masses called nuclei. In the 
spinal cord, the grey matter occupies the central axis. 
Homeostasis – The state of equilibrium, balance 
between opposing pressures, in the body with respect 
to various functions and to the chemical compositions 
of the fluids and tissues.  
Hyperfractionation – The dose per fraction is less than 
2Gy. 
Hypofractionation – The dose per fraction is greater 
than 2Gy. 
IMRT (Intensity Modulated Radiation Therapy) – 
Type of radiation treatment characterized with highly 
conformal dose distribution around the target using non-
uniform beam intensities, which is possible using static 
or dynamic segments. 
In vivo – Occurring in an artificial environment. 
In vitro – Occurring within the living body of an 
organism. 
Irradiation – Exposure to radiation, as in a nuclear 
reactor. 
Late responses – Radiation-induced normal tissue 
damage that in humans is expressed months to years 
after exposure. The α/β ratio tends to be small, 
normally, > 5Gy. 
Lethal dose (LD) – Dose of ionizing radiation enough 
to cause death. LD50 or MLD is the median lethal dose, 
what is the dose required to kill, within a specified 
period, half the individuals in a large group of organisms 
similarly exposed. For humans, LD50/60 is about 4Gy. 
Linear energy transfer (LET) – LET of charged 
particles in a medium is the quotient De/dl, where dE is 
the average energy locally imparted to the medium by a 
charged particle of specified energy in traversing a 
distance of dl [keV/µm]. 
Linear-quadratic model (LQ) – Used to describe the 
cell survival curve. 
Metastasis – Occurs when cancerous cells invade 
surrounding tissues, enter the circulatory system and 
establish new malignancies in body tissues distant from 
the site of the original tumor.  
Metastatic cancer – The stage of cancer is advanced 
in which cells from the primary site have spread, i.e., 
metastasized. 
Misrepair (error prone repair) – Reconstitution with a 
loss of information (e.g., deletion caused by the loss of 
a fragment of the molecule or mutation or translocation). 
Mitosis – Replication of a cell to form progeny cells with 
identical number (sets) of chromosomes. 
Mitotic death – Cell death related with a post-irradiation 
mitosis.  
Mitotic delay – As a result of treatment, delayed input 
into mitosis may occur due to accumulation of cells in 
the G2 phase. 
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Myelopathy – Any neurologic deficit related to the 
spinal cord. If its due to trauma, it is known as spinal 
cord injury. If it is inflammatory, it is known as myelitis. 
Disease that is vascular in nature is known as vascular 
myelopathy. 
Oligonucleotide – DNA polymer composed of only a 
few nucleotides. 
Oncologist – A physician who specializes in the study 
and treatment of neoplastic diseases, particularly in the 
treatment of cancer. 
Oncology – Science dealing with the physical, 
chemical, and biological features of neoplasms, 
including causation, pathogenesis, and treatment. 
Pathology – The branch of medicine treating of the 
essential nature of disease, especially of the changes in 
body tissues and organs that cause or are caused by 
disease. The study of diseased is realised both by gross 
and by microscopic examination of tissues removed 
during surgery and post-mortem. 
Peripheral nervous system (PNS) – 
Part of the vertebrate nervous system constituting the 
nerves outside the central nervous system and includin
g thecranial nerves, spinal nerves, and sympathetic an
d parasympathetic nervous systems. 
Posterior – Also called dorsal. Situated in the back. 
Opposite of the previous denomination. 
Probability – A mathematical ratio of the number of 
times something will occur to the total number of 
possible occurrences. 
Protocol – A detailed written set of instructions to guide 
the care of a patient or to assist the practitioner in the 
performance of a procedure developed specifically for 
tumors. 
Radiation – Electromagnetic radiation consists of wave 
motion of electric and magnetic fields. The photons 
have neither mass nor charge and have an energy 
inversely proportional to the wavelength of the wave. 
The electromagnetic spectrum is divided into radio 
waves, infrared light, visible light, ultraviolet light, and x-
rays, according to increasing photon energy and 
decreasing wavelength. 
Radiation (ionizing) – Energy transferred in the form 
of particles or electromagnetic waves of a wavelength 
of 100 nanometres or less (a frequency of 3 x 1015 hertz 
or more) capable of producing ions directly or indirectly. 
Radiation dose – The quantity of radiation what is 
absorbed for an irradiated object. It is expressed in gray 
(Gy), defined to be 1 J/kg. 
Radiation quality – For high-energy photons produced 
by clinical accelerators the beam quality (Q) is specified 
by the tissue–phantom ratio, TPR20,10. This is the ratio 
of the absorbed doses at depths of 20cm and 10cm in 
a water phantom, measured with a constant source–
chamber distance of 100cm and a field size of 10cm x 
10cm at the plane of the chamber. 
Radiation therapy – Use of ionizing radiation or any 
other type of radiation for the treatment of diseases. It 
is also called radiotherapy or actinotherapy. 
Radiobiology – Study of the scientific principles, 
mechanisms, and effects of the interaction of ionizing 
radiation on living matter. Also called as radiation 
biology.  
Radio-oncologist – Specialist physician with training in 
the use of radiotherapy, in order to reduce or cure 
patients with neoplasia. 
Radiosensitivity – Susceptibility of cells, tissues, 
organs or organisms to the effects of radiation, such as 
x-ray or other radiation. Result of radiation effect. 
Radiosensitizer – A chemical used to increase the 
radiosensitivity of cells to radiation. This substance 
mimics oxygen in fixing free radical damage. 
Radiotherapy – Type of treatment to combat a 
neoplasia using ionizing radiation. This type of 
treatment has as main objective to give an optimal dose 
of radiation in the place of interest, to cause the smaller 
possible damages to the normal tissues. Also called 
radiation therapy.  
Redistribution – Cells may exhibit different sensitivity 
depending on the phase of the cell cycle they are in. At 
the mitosis phase cells are more sensitive to DNA 
damage and late S phase are more resistant. With 
several dose fractions, there is progress in the cells 
through a new phase of the cell cycle. 
Reoxygenation – Occurs only in tumor cells. 
Phenomenon where hypoxic cells become oxygenated 
after a dose of radiation. 
Repair – Refers to the repair of the sublethal lesion. It 
occurs more efficiently in normal tissues, since tumor 
cells usually have more mitoses than the normal cells 
that generated them, uncontrolled cell cycle and 
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activation of the checkpoints for repair. Thus, by 
fractionating the treatment of the patient there is the 
possibility of repairing the normal tissues. 
Repopulation – Growth capacity of tumor cells that 
escaped radio-induced death. 
Save dose – is the maximum dose related to the body 
mass of a pharmacological agent that can be 
administered within 24 hours. 
SBRT (Stereotactic Body Radiation Therapy) – 
Involves stereotactic localization techniques combined 
with delivery of multiple small photon fields in a few 
high–dose fractions, for extracranial treatments, leading 
to a highly conformal dose delivery with steep dose 
gradients. Stereotactic localization techniques may 
include the use of relocatable rigid frames, image–
guidance techniques, and other positioning tools.  
Spinal cord – Part of the central nervous system, along 
with the brain. It is characterized as being a thick cord 
of nervous tissue within the spinal canal. In humans it 
gives rise to 31 pairs of spinal nerves. 
Stem cells – Non-specialized human cells that can 
produce all types of specialized cells in a lineage. 
Syndrome – Combination of characteristics and 
symptoms that are indicative of a disease or disorder. 
TCD50 – Radiation dose indicating that there is a 50% 
probability of tumor control. 
Therapeutic index (therapeutic ratio) – Tumoral 
response for a permanent level of normal-tissue 
damage. 
Tolerance – Maximum radiation dose prescribed by the 
therapist which is indicated as acceptable. It depends 
on several factors such as time between fractions, 
fractions indicated, field sizes and treatments previously 
performed. 
Tumor – Growth of cells abnormally. Tumors can be 
benign or malignant (cancerous). 
White matter – Constituted by myelinated nerve fibers. 
It belongs to the central nervous system (CNS).
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Chapter 1  
 
1. Introduction  
Radiotherapy (RT) is a cancer treatment based on the use of ionizing radiation, 
where a major evolution occurred over the years. Advances in medical imaging, dose 
planning and treatment delivery allowed to maximize tumor damage and to minimize 
the damage in the adjacent normal tissues. Radiobiology has achieved a prominent 
role over the years, which has contributed to evolution of radiotherapy. 
With improved delivery of radiotherapy treatments, survival rates have been 
increasing in many patients. This increase allowed the development of new tumors 
and local or regional recurrences, often within or near the previously irradiated site. 
When these situations occur, re-irradiation is a possibility that presents new 
challenges to radiation oncologists [5, 6]. 
One of the most important challenges posed by irradiation is the tolerance of organs 
at risk (OARs). Given that radiation has previously occurred, there are several factors 
to be considered so that complications in normal tissues do not overlap with the 
benefit that a new irradiation brings to the tumor. The spinal cord is considered an 
OAR because it is characterized by late complications that come from its irradiation, 
as is the case of radiogenic myelopathy. Since the spinal cord is the most dose-
limiting organ in radiotherapy, it is important to understand what factors should be 
considered with re-irradiation. The tolerance of spinal cord irradiation depends on the 
irradiated volume, total dose, dose per fraction, time between treatments and the 
spinal cord region involved. In this way it is expected to control the occurrence of late 
complications associated to this organ that can give rise to devastating functional 
deficits [5, 6]. 
In this work, we first present a review of the actual knowledge about the spinal cord, 
such as its anatomy and physiology. A special attention is given to radiobiology and 
its role in a course of radiotherapy. With the advancement of medical technology and 
with a higher life expectancy of patients, local and regional recurrence often appears, 
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and it is necessary to prescribe re-treatments. Thus, this work intends to answer 
several questions, such as: what maximum dose can be given in the first treatment 
so that a re-treatment can be performed, what maximum dose can be prescribed in 
a re-treatment without causing severe late effects, what is the time interval between 
treatments, and which type of RT treatment best applies to the patient's condition. 
Stereotactic body radiotherapy (SBRT) is an innovative RT treatment that aims to 
deliver with maximum precision the maximum possible radiation dose, in a small 
number of fractions (1 to 5 fractions) compared to conventional RT.  
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Chapter 2 
 
2. Theoretical concepts 
2.1 The role of radiation therapy 
Radiation therapy (RT) is a common treatment for various cancers and uses ionizing 
radiation to damage the deoxyribonucleic acid (DNA) of malignant cells, which usually 
replicate at a faster rate than normal cells in the body. Ionizing radiation deposits energy 
in the material along its path, being absorbed by the same material through various 
interactions. When radiation interactions occur, it breaks the molecular bonds of the DNA 
of the cells thus altering its structure. Through this mechanism, radiotherapy can prevent 
the replication of abnormal cells causing cellular dead [7, 8]. The different types of 
radiotherapy are shown in (Table 1). 
Table 1 Types of radiotherapy according to the type of target. Adapted from [5]. 
 
Radiotherapy may be used as a single or neoadjuvant treatment (treatment given prior 
to any other treatment) or adjuvant (treatment given after any other type of treatment 
such as surgery and chemotherapy) [7]. 
RT can be administered in the following ways (Table 2): internal radiotherapy 
(brachytherapy, intraoperative radiotherapy (IORT)) and external radiotherapy 
(stereotactic body radiotherapy (SBRT), three-dimensional conformal radiotherapy (3D-
CRT), radiotherapy modulated by intensity (IMRT), image-guided radiotherapy (IGRT) 
and radiosurgery). 
Types of radiotherapy  
Preventive radiotherapy Curative radiotherapy Palliative radiotherapy 
Prevention of possible metastases or 
recurrences through the application 
of radiotherapy. 
Tissue–tumor ratio is such that 
curative doses of radiation can be 
used without unduly harming normal 
tissue. 
Radiation therapy can be 
administered to relieve pain in cancer 
patients. 
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Table 2 Description of how radiotherapy can be administered to the patient [7]. 
 
 
The main objective of radiotherapy is to administer the prescription dose in the target 
volume, saving as much adjacent normal tissues as possible [7]. 
  
Type of treatment Description 
Brachytherapy  
Uses radioactive sources (temporary or permanent) 
placed near the target volume. These sources can be 
inserted directly into the tumor or placed through 
applicators previously inserted into a body cavity. 
Intraoperative radiotherapy (IORT) 
Administered under intraoperative conditions, usually by 
electron beams or low energy x-rays. It is used after 
resection of the primary tumor and external radiation 
therapy is usually necessary. 
External radiotherapy 
It involves the use of a linear accelerator to administer, 
outside the patient's body, radiation beams focused on 
the target volume to be treated. 
Stereotactic body radiotherapy (SBRT)  
Administered through multiple beams that are focused 
on a three-dimensional target. For tumors of the central 
nervous system (CNS) a thermoplastic mask is used, 
whereas for extracranial sites a body frame may or may 
not be used. 
Three-dimensional conformal radiotherapy (3D-CRT) 
Technique used where dose volume is made to fit the 
target using 3D anatomical data acquired from computed 
tomography (CT) or magnetic resonance imaging (MRI) 
imaging modalities. The goal is to apply the maximum 
dose to the target and save neighbouring structures as 
much as possible with the help of advanced computer 
hardware and software. 
Radiotherapy modulated by intensity (IMRT) 
It provides a highly conformal dose distribution around 
the target using non-uniform beam intensities, which is 
possible using static or dynamic segments. The isodose 
distribution can then be closely monitored by the target, 
modulating the intensity. 
Image-guided radiotherapy (IGRT) 
It uses various radiological and functional imaging 
techniques to perform high-precision radiotherapy. The 
main goals are to reduce the configuration and internal 
margins, and account for changes in target volume 
during radiation therapy, such as decreased tumor 
volume or weight loss (adaptive radiotherapy). 
Radiosurgery 
Can be performed by all kinds of advanced radiotherapy 
techniques, including IMRT, IGRT, synchronized 
respiratory radiotherapy, tumor-tracking radiotherapy 
and SRS/radiotherapy. 
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2.2 Radiobiology: essential concepts  
In radiation oncology, radiobiology is defined as the science that investigates the 
interactions between ionizing radiation and living systems, as well as the consequences 
of these interactions [7]. 
2.2.1 The role of radiobiology in the evolution of radiotherapy 
Radiobiology has allowed creation of new ideas and identification of potentially 
exploitable mechanisms in radiotherapy. According to experimental and theoretical 
studies in radiobiology, it was possible to verify that this area contributed through three 
different levels for the development of radiotherapy [9]: 
▪ Conceptual basis for radiotherapy: identifying the mechanisms and processes 
underlying the response of tumors and normal tissues to irradiation, which lead 
to the explanation of observed phenomena. The knowledge about the 5 Rs of 
radiotherapy is an example of the knowledge acquired through the conceptual 
basis; 
▪ Treatment strategies, allowing the development of new approaches in 
radiotherapy. Examples are the discovery of hypoxic cell sensitizers, high linear 
energy transfer (LET) radiotherapy and hyperfractionation; 
▪ Protocols, providing a more diverse range of treatment schemes in clinical 
radiotherapy. 
These three levels used by radiobiology are a starting point that provide insight into new 
options. Many treatment strategies produced through radiological investigation do not 
produce demonstrable clinical benefits. Creating protocols through experiments is a slow 
process. The ability of laboratory science to guide a radiation oncologist in the choice of 
specific protocols is limited by the inadequacy of theoretical and experimental models to 
clinical practice [9]. 
2.2.1.1 Radiobiological mechanisms  
In the exposure of living tissues to ionizing radiation absorption of photon energy by cells 
occurs. The radiation through the biological material will trigger a series of events, 
interact with the atoms and molecules of the medium, with the consequent transfer of 
energy. 
There is strong evidence that DNA is the target of the biological effects of ionizing 
radiation, namely cell death, loss of clonogenic capacity, genetic mutations and 
6 
 
chromosomal aberrations, with consequent somatic, hereditary, teratogenic and 
carcinogenic effects. 
Ionizing radiation causes damage to cells or tissues by depositing energy in a sequence 
of events. Different types of radiation have distinct abilities to cause biological damage. 
All these lesions are caused at the cellular or molecular level. The biological effects 
subsequently manifested are due to the impact of these lesions on millions of cells in an 
organ or tissue. Considering that the nature of the damage is molecular or cellular, it is 
therefore essential to understand the mechanisms involved. 
Ionizing radiation, used in radiotherapy, causes a cascade of events, which begins 
immediately after its emission. The initial ionization (physical phase) is followed by 
immediate damage of vital macromolecules at the cellular level – direct effect, or 
indirectly through interaction with water molecules, resulting in free radicals of oxygen, 
highly reactive at the molecular level (physical–chemical phase) – indirect effect. 
 
The energy deposited initially by ionizing radiation is used in the formation of free 
radicals. Since the cells are mainly composed of water, most of the lesions caused by x-
rays to biological molecules - about 2/3, are mediated through free radicals, namely 
hydroxyl radicals. The free radicals resulting from these reactions initiate complex 
Figure 1 Time scale of the effects of ionizing radiation: biological changes manifest after a period of latency 
that can go from minutes to weeks to years after exposure (A - early effects; B - late effects). 
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chemical reactions, which can lead to the destruction or inactivation of vital molecules in 
the cell. Chemical phase follows in which sub-lethal damage repair can occur. Then, 
during the biological phase, the manifestation of unrepaired lesions in the DNA occurs. 
These 3 different phases described previously differ in time scale (Figure 1) [9]: 
1) Physical phase (about 10-18sec) – phase where photon energy deposition occurs 
to the orbital electrons, exciting or ionizing them; 
2) Physical–chemical phase (about 10-13sec) – the breakdown of chemical bonds 
caused by excited or ionized atoms occurs. These atoms can cause damage to 
important molecules, such as DNA, in a direct way or through the formation of 
free radicals; 
3) Chemical phase (seconds to years) – constituted by the reaction of the cells to 
the damages caused by the radiation. Damage to DNA can be repaired by 
specific enzymes, but some are irreparable leading to cell death. Cell death is not 
immediate occurring in most cell division after irradiation (and may occur up to 5 
or 6 cycles after). 
The main function of radiobiology is to observe the phenomena that occur with 
irradiation of the tumor and normal tissues, suggesting improvements to the existing 
therapeutic options. The tumor response to irradiation is called regression and may 
be followed by recurrence. If tumor recurrence does not occur during the patient's 
life, local tumor control may be considered to exist [9]. 
Thus, when a cell absorbs radiation 4 possibilities can occur: 
▪ Absorption of the radiation may have no adverse effects, or if injury occurs, it 
may be repaired without any trace of exposure occurring; if not repaired, the 
apoptosis pathway may be activated; 
▪ Cell can suffer lethal, irreparable and irreversible damage, leading to cell 
death; 
▪ Cell may lose its clonogenic capacity; 
▪ Gene mutations may occur, with distinct consequences depending on the 
type of cell where they occur. 
The most frequent cause of radiation-induced cell death is the inability to correct double 
lesions in the DNA strand and manifests itself when the cell attempts subsequent cell 
division. In this way, more proliferative cells manifest damage or die much earlier than 
cells with longer proliferation times. Thus, biological changes in cells and tissues due to 
ionizing radiation occur only after a latency period, which may range from minutes to 
8 
 
weeks or even years (as a function of dose, dose rate, cell kinetics, control of cycle 
regulating genes cell phone, etc.). 
Genetic and biochemical constitution is a determining factor in the molecular response 
to radiation, and several molecules are already identified through which cells detect 
radio-induced lesions. 
Recognition of these lesions activates signal transduction pathways suitable for cellular 
response to injury. This process is influenced by internal cell signalling processes as well 
as external factors such as hypoxia, cytokines, intercellular contact and extracellular 
matrix. The result of these interactions may promote cell survival or death, cell cycle 
arrest or blockage, and DNA repair or genetic instability, depending on how the cells 
respond to radio-induced lesions. 
Thus, while initial energy deposition and subsequent events occur in 10-18–10-13 sec, the 
chain of biological effects that begins by inducing programmed cell death or repairing 
sublethal and potentially lethal damage, leading to tissue repair and remodelling can take 
minutes, hours, days, months or years to express these effects. 
There are also several factors that affect the cell response to radiation: physical factors 
(dose, dose rate, fractionation, LET - linear energy transfer - and RBE - relative biological 
efficacy); chemical factors (radiosensitizers, radioprotectants, O2 tension) and biological 
factors (proliferative state, cell cycle phase, physiological or metabolic state, genetic 
constitution of the cell) - reviewed in [10]. 
 
2.2.1.2 Cell cycle control  
The concept of cell cycle is essential for the knowledge of all cellular radiobiology 
processes. It is a necessary process that involves great fidelity and of extreme 
importance for the propagation of organisms (Figure 2). 
The cell cycle consists of a succession of events that lead to duplication of genetic 
material and other cellular components and eventually cell division (Table 3). 
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Table 3 Phases of the cell cycle: representation and description. 
 Cell cycle Description  
G1 phase (gap) 
The synthesis of enzymes involved in DNA replication 
occurs; 
S phase 
The cell generates an integral copy of the genetic 
material, proceeding to a second preparatory phase of 
cell division; 
G2 phase Occurs before entering mitosis. 
Mitosis (M) 
The DNA replicate is condensed into compact 
chromosomes, segregated into the daughter cells so 
that each one receives a complete copy of the genetic 
material. 
G0 phase 
Period in which the quiescent cell maintains its 
metabolic activity but does not grow unless it receives 
extracellular signals. 
 
For cell cycle progression to occur, a DNA check system is required to ensure complete 
duplication of the genome in an orderly and highly faithful manner. Changes in normal 
cell cycle control lead to genetic instability, a major factor in carcinogenesis. This is why 
the existence of checkpoints for the integrity and state of the replication of the genetic 
material that allows the stop of the cell cycle progression in case of damage or mutation 
of the DNA, so that it is evaluated and repaired, ensures the complexity and irreversibility 
of the cell cycle, as well as the processes of activation, expression and degradation of 
the proteins involved. On the other hand, physiological cell death in self-regulating 
tissues, such as the skin, intestine and bone marrow, is necessary to give rise to the 
cells that are constantly formed: it is programmed cell death also called apoptosis. In this 
Figure 2 Role of cyclins and cyclin-dependent kinases (CDKs) in cell cycle regulation: The cell cycle is 
divided into G1, S (DNA synthesis), G2 and M (mitosis) phases. The transition between phases is controlled 
by cyclins and CDKs. 
G1 
G0 
G2 
S 
M 
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process, where several regulatory genes and a family of proteases, the caspases, are 
involved, the cells are fragmented into membrane-bound corpuscles, with consequent 
phagocytosis by neighbouring cells, with no inflammatory response. 
Failure to induce apoptosis contributes to carcinogenesis by allowing the occurrence of 
genetic instability and the deregulation of the activity of the genes involved in cell cycle 
control and their checkpoints. During the regulation processes, the cell activates and 
inactivates the proteins by addition by the kinases or removal by the phosphatases of 
the phosphate groups, respectively. For faster and more effective kinases and 
phosphatases can physically bind to the protein they modify, with formation of 
multiprotein complexes [11]. 
The p53 gene, known as the "guardian of the genome", is a tumor suppressor gene that 
encodes a nuclear phosphoprotein that, because of its physiological functions, ensures 
cellular genetic integrity: cell cycle regulation, apoptosis control and DNA repair (Figure 
3). 
 
 
 
 
 
 
 
 
 
When DNA damage occurs, the p53 protein is responsible for the temporary stopping of 
the cell cycle in G1 for repair or, when this is not possible, the process of cell apoptosis 
begins. Thus, if p53 mutation occurs, the functions of the protein may not be activated, 
and the consequence will be uncontrolled cell proliferation. Mutations of this gene are 
described in more than 50% of human tumors, conferring a proliferative advantage on 
Figure 3 p53 Injury recognition process: under normal conditions the protein expressed by the p53 gene is 
responsible for the temporary stopping of the G1 cell cycle for DNA repair or, if not possible, programmed 
cell death (apoptosis). If the gene is mutated, the functions of p53 are not activated and the result will be 
uncontrolled cell proliferation. 
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cells carrying the mutation. Apoptosis is one of the best studied processes in cell death 
by ionizing radiation and depends on p53. Cells with mutations in this gene do not 
undergo apoptosis after treatment with ionizing radiation, unlike in cells where the p53 
gene is active [12]. 
2.2.1.3 Proliferation and differentiation  
The concept of cell proliferation and its influence on response to treatment is crucial in 
RT. Cell proliferation in normal tissues, unlike in tumors, is very well organized through 
homeostatic control: there is a balance between cell production and the loss of more 
differentiated cells. Radiation is a unique cytotoxic agent because lesions caused to DNA 
can remain inactive for hours, days, weeks or months. This occurs because in the clear 
majority of normal and tumor tissues, cell death only occurs when the cell attempts the 
next division, which depends on the proliferative characteristics of the tissue. In cells of 
the intestinal mucosa, in which cell cycle time (Tc) is short (12-24h), cell death occurs 
after a few hours: in the skin (Tc = 4 days), may take a week; in the kidney (Tc 
indeterminate) can take months [13]. 
As at the cellular level there are preferential targets for the action of radiation, also at the 
tissue level there are cells or groups of cells more sensitive or whose death depends on 
the changes observed in the body after irradiation. The different organs or tissues of the 
living organism are composed of several cell types and the response of an organ or 
tissue to the radiation depends on the intrinsic sensitivity of the different cellular 
populations in that organ or tissue and the proliferative characteristics of each population. 
The Law of Rubin and Casarett differentiates tissue sensitivity – being that this is 
essentially a function of the type of cell that constitutes the tissue – in five distinct groups. 
In the first group are the most sensitive cells, as they are those that are more 
metabolically active, divide more quickly and more undifferentiated. In the second group 
are the differentiated, intermittent cells, the result of the cell division of the cells of the 
previous group, which are still very active and relatively undifferentiated mitotically. In 
the intermediate group, which includes connective tissue cells, we find vascular 
endothelial cells and fibroblasts. In the following groups cell differentiation increases and 
proliferation decreases until the last classification, which includes fixed postmitotic cells, 
where we find examples of the most resistant cells [14].  
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2.2.1.4 Tolerance of normal tissues to radiation  
Cellular organization in proliferative and functional compartments has important 
consequences for tissue response to radiation. In this way, the tissues can be divided 
into 2 categories. 
In the first category - hierarchical cell organization - tissues that have a clear 
separation between the proliferative compartment (including the population of stem cells, 
capable of unlimited self-renewal; the amplification compartment - cells that proliferate 
rapidly but only over a limited number of cell divisions), and the differentiated cell 
compartment, responsible for organ / tissue functions. As examples we have the most 
proliferative tissues such as the hematopoietic system, the cells of the basal layer of the 
epidermis and the lining of the gastro-intestinal system and the spinal cord. 
The begin of the acute reactions of these tissues to the radiation is correlated with the 
life span of the differentiated functional cells, and the intensity of these reactions reflects 
the ratio between the rate of destruction of the stem cells and the rate of regeneration of 
the surviving clonogenic cells. 
In the second category - flexible cell organization - tissues are included in which there 
is no clear separation between the two compartments but in which some differentiated 
cells also exhibit self-renewal capacity. In this type of organ/ tissue with a low proliferation 
rate (kidney, lung), the relationship between cell death and tissue response is less 
evident because organ damage can occur due to changes in vascular, connective or 
parenchymal tissue. 
Late effects are not only restricted to these slow cell renovation tissues. For example, in 
epithelial tissue, late lesions - fibrosis, atrophy and telangiectasia - may occur in addition 
to early reactions. Thus, different types of lesions may occur sequentially in an organ or 
tissue, resulting from distinct mechanisms and cellular interactions.  
The difference between acute and late effects can be explained by their progression: 
while the acute effects are quickly repaired by the high proliferation of stem cells and can 
be completely reversible, the late effects can be attenuated but never completely 
repaired as they result from the association of vascular lesions with loss of parenchymal 
cells. 
This distinction has relevant biological consequences: as acute reactions occur during 
conventional RT treatment, it is possible to make the necessary changes to allow the 
survival of stem cells that will repopulate and ensure cell proliferation. Late effects, which 
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occur months or years after RT, are much more sensitive to changes in fractionation than 
early effects. 
Tolerance of normal tissues may also be influenced by treatment-related variables (total 
dose and dose per fraction, dose rate, total time of treatment, energy and volume 
irradiated, use of concomitant chemotherapy), patient (age, comorbidity associated with 
diabetes, vascular disease), or with the organ in question (development of radiation 
toxicity, variation in intrinsic radiosensitivity of the organ) - reviewed in [15]. 
2.2.1.5 Rs of radiobiology 
The complexity of the response to RT increases with the characteristics of the 
surrounding normal tissues: while cells and tissues may respond differently to the same 
dose of radiation, the response of a tissue is strongly determined by the rate of cell 
proliferation and tissue repopulation capacity in addition to the molecular and cellular 
factors that determine intrinsic cellular radiosensitivity. 
Tumor responses show greater variability than normal tissues and these biological 
differences are explored in dose fractionation in radiotherapy, where the protocols are 
derived empirically but exploit differences in biological response between normal and 
tumor tissues at the same dose of radiation. The biological factors that influence the 
response of normal and tumor triglycerides to RT were summarized by Withers (1975) 
as the radiotherapy Rs [16]. 
Radiotherapy given in a single, high dose fraction is ineffective for tumor control and has 
serious side effects. To reduce these effects, radiotherapy was given in small fractions 
daily and at low doses and this type of treatment was referred to as fractional 
radiotherapy [7]. 
Fractional radiotherapy is based on five main features known as the "Rs of radiobiology". 
These are described then in order of occurrence, i.e., the first biological mechanism 
observed is the repair of sub-lethal damage, followed by redistribution of cells in the cell 
cycle, reoxygenation, and finally repopulation [7]. 
The classical fractionation principles, i.e., the Rs of radiobiology, explain the effects of 
high doses of ionizing radiation on tumors and adjacent normal tissues. The outcome of 
standard clinical radiation treatment is determined by the Rs of radiobiology. 
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2.2.1.5.1 Repair of sub-lethal damage 
In the literature, this mechanism can be called in several ways: "repair", "repair of DNA 
damage" or "repair of sub-lethal damage". 
 
Repair of sublethal DNA damage: normal cell are more effective than tumor cells in this 
process as observed from cell recovery in the 2 hour period after exposure to ionizing 
radiation. Radiation randomly interacts with molecules in the cell, but DNA is the main 
target molecule for the biological effects of radiation, including cell killing, carcinogenesis 
and mutation. In radiotherapy radiation damage is primarily manifested by the loss of 
reproductive capacity. Radiation causes a wide range of lesions in DNA such as single 
(SSB) and double-strand breaks (DSB) in the sugar-phosphate backbone of the DNA 
molecule. SSB can be readily repaired using the undamaged chromatid as a template. 
The most deleterious lesion induced by ionizing radiation is DSB, a break in both strands 
of 10 base pairs or less. There are several mechanisms to repair DSBs, which indicate 
the importance and difficulty of repairing this type of DNA injury. The most important are 
non-homologous end joining (NHEJ) and homologous recombination (HR). Homologous 
recombination provides greater repair accuracy than NHEJ, the major pathway to repair 
DSB throughout all the phases of the cell cycle [17]. 
 
Radiotherapy cause lethal damage to tumor cells and sublethal damage to normal tissue 
cells. Sub-lethal damage can be repaired if enough time is given between exposures to 
radiation. If the cell is exposed to radiation before the repair occurs, the damage can 
become lethal, i.e., the sum of the damages caused leads to the repair not being viable 
and cell death occurs (Table 4) [7]. 
Normal tissue cells that have a late response to radiation can repair faster than tumor 
cells, if there is an ideal range between fractions of 6-12h [7]. 
Different types of cells have distinct abilities to correct radiation-induced damage, and 
some cells having been verified to be faster compared to others to repair sub-lethal 
damage [9]. 
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Table 4 Characteristics of different types of cell death. Adapted from [9]. 
 Morphological changes 
Types of cell death Nucleus Cell membrane Cytoplasm Biochemical features 
Apoptosis 
Condensation of 
chromatin, nuclear 
fragmentation; DNA 
laddering 
Blebbing Fragmentation Caspase-dependent 
Autophagy 
Partial chromatin 
condensation; 
Blebbing Autophagic vesicles 
Caspase-
independent 
Necrosis 
Degradation of 
nuclear DNA 
Swelling and rupture 
Organelle 
degeneration and 
mitochondrial 
dilatation 
- 
Senescence 
Distinct 
heterochromatic 
structure 
- 
increased granularity 
and flattening 
SA-β-gal activity 
Mitotic catastrophe 
nuclear 
fragmentation and 
dicentric 
chromosomes. 
- - 
Caspase-
independent (at 
early stage) 
 
It is relevant to distinguish two processes that are commonly accepted as the same: 
repair and recovery. While the first refers to the method in which the cell corrects a 
radiation-induced error, recovery is understood as the ability of a tissue, not a cell, to 
increase its cellular survival or decrease the damage caused if it has sufficient time for 
this process to occur, such as the recovery of an erythema. 
Repair is due to the correction of sub-lethal damage and can be measured, for example 
by a sequence of irradiances separated by variable time interval. On the other hand, 
recovery may involve the recruitment of cells that are in a non-division phase, G0, to 
enter the cell cycle and thus compensate for cell death [9]. 
2.2.1.5.2 Redistribution of cells in the cell cycle 
Cell cycle consists of four distinct and consecutive phases (Figure 4) [9]: 
▪ Phase G1 and G2, which are periods of apparent inactivity (gap), where the G1 
phase occurs before S phase and the G2 phase between synthesis and mitosis; 
▪ Phase M corresponds to the phase of mitosis; 
▪ Phase S, which is the period where the synthesis of genetic material occurs to 
proceed to the division. 
 
16 
 
 
 
 
 
 
 
 
 
 
 
Redistribution: when radiotherapy is given to a heterogenous cell population, cells may 
be in different phases of the cell cycle. Cells in S phase are more radioresistant and cells 
in late G2 and M phases are more sensitive. A small dose of radiation will destroy the 
more sensitive cells, and a resistant cell population that is now synchronized survives.  
As fractionated radiotherapy treatment continues, the resistant surviving cells will 
continue throughout the cell cycle and when a new dose is delivered some of these cells 
have moved from a resistant to a more sensitive stage and will then be killed more easily 
(Figure 5) [19]. 
 
 
 
 
 
 
 
 
 
 
Figure 4 Representation of the cell cycle. Adapted from [18]. 
Figure 5 Cell cycle and survival curve phases. Adapted from [7]. 
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2.2.1.5.3 Reoxygenation 
As tumor volume increases through tumor cell proliferation, vascularization does not 
accompany this tumor growth, becoming insufficient to meet its requirements and 
hypoxic regions begin to appear in tumor tissue. Hypoxic cells are 2-3 times more 
resistant to radiation, and well-oxygenated cells are eliminated during treatment of 
fractionated radiotherapy. Since oxygen supply is constant, hypoxic cells gradually gain 
vascularity and oxygenation, and the output radiosensitivity increases [7]. 
Reoxigenation:  The level of oxygenation in a tumor is a major determinant of the 
effectiveness of radiotherapy. Tumor cell microenvironment presents areas with 
decreased pH, lack of nutrients and hypoxia. Oxygen concentration (pO2) varies 
between 10- and 80-mm Hg in normal tissues but in tumors these values can be lower 
than 5 mm Hg in some areas. This anomaly is due to the development of abnormal 
vasculature during tumor angiogenesis.  A significant proportion of tumor cells is hypoxic, 
showing great heterogeneity that is not correlated with standard prognostic factors such 
as size, stage and histological type [20]. 
Hypoxia may have a crucial role in treatment outcome and may also influence metastatic 
capacity of tumor cells resulting from genetic changes such as those involving blood 
oxygen transport or inducing vascularization. As a result of prolonged exposure to 
hypoxia, cells can acquire genetic resistance to apoptosis suggesting that hypoxia can 
favour tumor progression through clonal selection of cells with more aggressive 
phenotypes [21].   
After an initial dose of radiotherapy, the more sensitive oxygenated cells are killed; during 
reoxygenation, surviving tumor hypoxic cells can increase their oxygen supply thus 
increasing their sensitivity to radiation. Biological efficacy of ionizing radiation relies on 
oxygen interacting with cells and making DNA lesions permanent [22]. 
Prolonged exposure to hypoxia can induce tumor death by apoptosis, as cells with 
mutations in the p53 gene acquire genetic resistance to hypoxia-mediated apoptosis, 
suggesting that hypoxia may favour tumor progression by selecting cells with mutations 
in p53 [19]. Other studies suggest that cells in hypoxia may develop genomic instability 
or that these cells may reduce the functionality of proteins involved in DNA repair [23]. 
After a first dose in the treatment of RT, the more sensitive oxygenated cells are 
eliminated; the surviving tumor cells are in hypoxia but later, during treatment, their O2 
supply can improve, increasing the sensitivity to radiation. The biological efficacy of 
18 
 
ionizing radiation depends on the presence of oxygen, which reacts with the cells making 
the DNA lesions permanent [24].  
The division of the dose into several fractions spares the normal tissue due to the 
occurrence of repair of the sublethal damages and the cellular repopulation that occurs 
between the fractions. Simultaneously, fractionation allows for greater damage to the 
tumor caused by reoxygenation of hypoxic cells and the redistribution of cells to more 
radiosensitive phases of the cell cycle. 
To oxygenate a tumor in the hypoxic state [7]: 
▪ If the haemoglobin value is low, a blood transfusion can be given to the patient; 
▪ High pressure oxygen may be applied during radiotherapy; 
▪ The patient may be prevented from using hypoxic materials, such as cigarettes, 
during radiation therapy; 
▪ Hypoxic radiosensitizers may be used, such as metronidazole. 
 
2.2.1.5.4 Repopulation  
Repopulation: Some time after irradiation an increase in cell division is seen in normal 
and malignant cells. Repopulation occurs at different rates depending on the tissues and 
represents cell proliferation that aims at compensating the cell population that was killed.  
This homeostatic response to cell loss occurs in situations other than irradiation and is 
related to specific cell-cycle time: as a result of radiotherapy cell death occurs after 
irradiated cells attempt mitosis and thus highly proliferative tissues (and tumors) show 
damage much faster than slowly proliferative tissues. 
Normal and tumor cells continue to proliferate when exposed to radiation. This 
proliferation is a physiological response of tissues to a decrease in cell numbers. The 
proliferation of the cells leads to two main consequences, such as the increase in the 
number of tumor cells to be destroyed, which is against the stipulated treatment, and the 
increase in the number of normal cells after irradiation, which is in favour of the treatment 
[7]. 
Repopulation allows tumor cells to resist the lethal effects of radiation therapy. 
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2.2.1.5.5 Radiosensitivity 
The fifth "R", radiosensitivity is a concept that can be affected by the cell 
microenvironmental conditions. Bergonie and Tribendau, in 1907, defined that 
radiosensitivity was directly proportional to mitosis and inversely proportional to cell 
differentiation [7]. 
To summarize, considering t as the time between fractions and T the total treatment time 
(Table 5) [7]: 
Table 5 Influence of time t and T according to the "R". Adapted from: [7]. 
Rs Description 
Repair T should be minimum for normal tissues 
Redistribution t should be minimum 
Reoxygenation T should be minimum 
Repopulation T should be minimum for the tumor 
 
Dividing total dose in several fractions saves normal tissue due to sublethal damage 
repair and cell repopulation occurring between treatment fractions. At the same time 
fractionation allows greater damage to the tumor as a result of reoxygenation of hypoxic 
cells as well as redistribution of cells into more radiosensitive stages of the cell cycle. 
Therefore, DNA repair and cell repopulation mechanisms induce normal tissues to 
become more resistant to a following dose of radiation; the other Rs, namely 
redistribution and reoxygenation have the opposite effect increasing radiosensitivity of 
tumor cells. The Rs represent the factors that modify tissue response to fractionated 
radiotherapy - overall radiosensitivity of a specific tumor depends upon a 5th R: 
Radiosensitivity [25], that translates the outcome of all the other Rs and represents 
individual sensitivity to radiation. These five fundamental factors represent the biological 
basis of radiotherapy. 
2.2.2 Cell survival curves 
The cell survival curve describes the ratio between the fraction of surviving cells, i.e., the 
fraction of irradiated cells that maintains their reproductive integrity, and the dose 
absorbed. Cell survival is plotted with the dose on the x-axis and the fraction of surviving 
cells on the y-axis [24]. 
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The number of cells inserted into cell lines and cultures can increase in two ways: 
arithmetically and exponentially (Figure 6). The number of cells increases linearly with 
each generation in an arithmetic increase. On the other hand, in the exponential 
increase, the number of cells doubles with each generation and thus the exponential 
growth is faster when compared with the arithmetic growth [7]. 
The type of radiation used influences the way the cell survival curve takes. The ionizing 
radiations that have high linear energy transfer (LET) (densely ionizing radiations) result 
in a curve similar to an exponential function. On the other hand, ionizing radiations that 
have low LET (sparsely ionizing radiations) present curves with an initial inclination and 
become almost straight when the doses are higher [26]. 
The factors that make cells less radiosensitive are [26]: 
▪ Removal of oxygen, making the cells hypoxic; 
▪ Addition of chemical components as free radical catalysts; 
▪ Use of low doses or fractional irradiation; 
▪ Irradiation of cells in the late S phase of the cell cycle. 
Cell survival curves are an example of dose-response curves and are widely used in the 
field of radiobiology when developing the Linear Quadratic model [9]. 
According to the linear quadratic model (LQ), the fraction of surviving cells can be 
calculated (Eq.1) [26]: 
𝑆(𝐷) = 𝑒−𝛼𝐷−𝛽𝐷
2
 (𝐸𝑞. 1) 
Where: 
▪ S represents the fraction of surviving cells at a dose (D); 
▪ α is a constant that describes the initial inclination of the survival curve; 
▪ β is a small constant that describes the quadratic component of cell death. 
Figure 6 Curves of cellular survival: 1) arithmetic, 2) geometric and 3) Exponential increase in cell 
number. Adapted from [7]. 
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From the analysis of the cell survival curve it is possible to extract information on both 
the number of cells killed by the ionizing radiation and the radiosensitivity of the cell. In 
this way, it is important to define the parameters α and β. These are both radiosensitivity 
parameters, since α is the parameter that measures the amount of lethal damage and β 
is the parameter that measures the amount of sublethal damage [7, 9]. 
 
2.2.3 Dose-response relationship 
The purpose of radiotherapy is to provide enough radiation to the tumor to destroy it, 
considering the protection of the surrounding normal tissues. These tissues should be 
protected from a dose that can lead to serious complications, i.e., morbidity [9]. 
When there is a change in treatment strategy it is necessary to consider both the effects 
on tumor response and damage to normal tissues. By analysing these two parameters it 
is possible to evaluate the existing options. If on the one hand the benefits are related to 
the tumor response, on the other the damages are evident in the normal tissues. There 
are also other factors that weigh on this type of decision, namely little quantifiable 
aspects such as new forms of toxicity or risks to the patient, among others. The role of 
radiobiology is to ensure an approach to the quantifiable biological aspects inherent in a 
change of treatment [9]. 
Radiobiology applied to clinical radiotherapy has as main interest the relation between a 
certain absorbed dose of radiation and the biological response. As the radiation dose 
increases, the radiation effects can increase in degree and/or incidence. In most cases, 
the interest is to know the relationship between dose and incidence. The dose-response 
curves take a sigmoid (S) form, with the incidence tending to zero as the dose tends to 
zero and the incidence tends to 100% at very large doses. This applies to tumor control 
as to normal tissue complications [21]. 
The tumor control probability (TCP) is plotted as a function of the total dose and the 
incidence of normal tissue complications is also plotted as a dose function. The exposed 
figure 7 represents a favorable situation because it shows that the tumor is more 
radiosensitive compared to normal tissue [21]. 
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The optimal choice of the radiation dose delivery strategy in a tumor occurs when TCP 
is maximized and NTCP is minimized. For a good radiotherapy treatment TCP ≥ 0.5 and 
NTCP ≤ 0.05. Observing figure 7, we can see that as the dose of radiation increases, 
the tumor response increases and so does tumor tissue damage and consequent 
complications [26]. 
Figure 7 shows an ideal situation; in reality, the TCP curve is often shallower than the 
NTCP curve, partly because tumors are more heterogeneous than normal tissues. In 
addition to this fact, the TCP curve never reaches a value of 1.0 due to possible 
microscopic or metastatic spread beyond the primary tumor. To perform a good 
radiotherapy treatment, it is essential that the mean doses of normal tissues be kept 
lower than the tumor doses, to minimize the inherent complications of the treatment and 
to optimize the results [26]. 
At the beginning of radiation therapy normal tissue cells were thought to be more 
radioresistant to single doses of radiation than tumor cells. However, it has now been 
found that both malignant cells and acute response tissue cells have an 𝛼 𝛽⁄   ratio of 
10Gy [26]. 
The term therapeutic index describes the tumor response to a fixed level of normal tissue 
damage, translating the notion of the "cost-benefit" analysis of a radiotherapy treatment. 
This index varies according to several factors, namely with the dose rate and LET of the 
Figure 7 Principle of therapeutic index. Curve A: Probability of tumor control (TCP); Curve B: Probability of   
complications (NTCP). Adapted from: [21, 26]. 
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irradiation, with the presence of radiosensitizers or radioprotectors, with the treatment 
plan and with the precision of administration of the treatment [9, 26]. 
Relatively to the term therapeutic window this consists of the difference between the 
dose of tumor control and the dose of tolerance. The larger the therapeutic window the 
more radiosensitive the tumor, because a smaller dose is needed to obtain the tumor 
control and a greater dose for the appearance of complications. The lower the 
therapeutic window, the more radioresistance is the tumor [9]. 
 
2.2.4 Biologically Effective Dose (BED) 
In 1982, Barendsen achieved a major advance in the use of linear quadratic algorithms. 
The extrapolated tolerance dose (ETD) is defined as a dose administered in infinitely 
small fraction doses or at an infinitely low dose rate, generating the same cell death. The 
term ETD was renamed by extrapolated response dose (ERD) when it was concluded 
that it could be applied to all types of biological effects and not only to tolerance of normal 
tissues. Subsequently, the term biologically effective dose, BED, was adopted. The term 
ERD is currently used by Dutch scientists [27, 28]. 
In 1989 an article was published, by the British Journal of Radiology, which introduced 
the term BED. It is based on the linear quadratic model with the included time factor, 
substituting terms as the standard nominal dose of 1969. BED is used in iso-effective 
fraction dose calculations. Over the years, it has undergone several improvements that 
have allowed its clinical utility to be extended, particularly in the comparison of dose 
fractionation schemes used in different institutions. When BED calculations are the only 
data available in a complex treatment, weighting in the analysis of these data is 
necessary [29]. 
The term BED represents the cell survival model, is an inherent part of the quadratic 
linear model and indicates the radiosensitivity of normal or tumor cells to the effect of 
radiation. The theoretical framework of the model is needed to help understand the term 
BED, which is explained in Annex A in the section "Appendix A" [29]. 
BED represents the physical dose required to achieve a given effect if the dose was 
administered by infinitely small fraction doses or at a very low dose rate in the case of 
continuous irradiation rates [29]. 
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Using the BED, it is possible to overcome the difficulty in clinical practice of calculating 
the total dose when a dose change occurs per fraction, through Eq.2 and Eq.3: 
𝐵𝐸𝐷 =
𝐸
𝛼
=
𝑛(𝛼𝑑 + 𝛽𝑑2)
𝛼
= 𝑛𝑑 [1 +
𝑑
(𝛼 𝛽⁄  )
]  (𝐸𝑞. 2) 
                                        𝐵𝐸𝐷 = 𝐷 [1 +
𝑑
(𝛼 𝛽⁄  )
] (𝐸𝑞. 3) 
Equation 3 represents the most commonly used formula for BED calculations.  
BED is the parameter which quantifies the overall biological effect on a given tissue. The 
equation for BED provides a simple and straightforward way to compare doses from 
different fractionation schemes, which in turn have different biological effects [29, 30, 
31]. 
For each treatment of radiotherapy performed, there are at least two BED values: that of 
the tumor and that of the late response tissues. Usually treatments can be compared 
using as reference the BED values associated with each. BED is useful in the decision 
process as compensating for interrupted treatment [32]. 
Based on experimental and theoretical considerations, this model is mechanically 
plausible for designing protocols in the dose range up to 10Gy/fraction, and, based on 
animal data, it is reasonable up to 15 to 18Gy per fraction [33]. 
 
2.2.4.1 Values of the 𝛼 𝛽 ⁄ ratio 
The increase in BED values is higher in tissues with low 𝛼 𝛽⁄  ratios, i.e., it is higher in late 
response tissues than in acute response tissues [7, 27]. For acute response tissues the 
𝛼
𝛽⁄  ratio is within a range of 7-20Gy, whereas for late response tissues the 
𝛼
𝛽⁄  ratio 
generally ranges from 0.5-6Gy. 
Concerning 𝛼 𝛽⁄  ratio values for tumor tissues, it should be noted that the values 
presented by the well-oxygenated head and neck carcinomas and lung carcinomas are 
identical or slightly higher than the values presented by the acute response tissues. 
However, there is evidence that some tumors, such as melanomas, sarcomas, early-
stage prostate tumors and breast tumors, have low 𝛼 𝛽⁄  ratios. These may also present 
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even lower values than those concerning normal late response tissue, namely 0.8-2.5Gy 
for slow-growing prostate tumors [9, 29]. 
The 𝛼 𝛽⁄  values for cervical and thoracic cord are 2Gy and 4Gy, respectively. In this way, 
a dose of 50Gy given in 2Gy daily fractions is equivalent to a BED of 100Gy2 (𝛼 𝛽⁄ = 2) 
or 75Gy4 (𝛼 𝛽⁄ = 4). 
 
2.2.4.2 Hypofractionation and hyperfractionation 
When the dose per fraction is greater than 2Gy it is said that the alternative fractionation 
scheme is termed as hypofractionation. In this case, BED values decrease more rapidly 
in late response tissues than in acute response tissues. However, when the dose per 
fraction is less than 2Gy, we are talking about a case of hyperfractionation where BED 
values increase more rapidly in late response tissues [9]. 
Late response tissues are more sensitive to a dose modification by fraction, since the 
change in the total dose is higher for lower 𝛼 𝛽⁄  ratio values. Hypofractionation can be 
used as a convenient way of accelerating treatment, i.e., reducing its total time. In some 
types of tumors, this implementation can lead to short schedules that can be favourably 
compared with longer schedules in terms of tumor control and late response tissue 
effects. It is important to note that the advantage associated with a lower fraction dose 
would be voided for tumors with low 𝛼 𝛽⁄ values [9]. 
 
2.2.4.3 Dose equivalent in fractions of 2Gy (EQD2) 
The approach of the LQ model leads to several formulas that allow us to calculate the 
isoeffect ratios for radiotherapy. These formulas are intended to describe a set of 
fractionation schemes that are isoeffect. The simplest method of comparing the efficacy 
of schemes consisting of different total doses per fraction is to convert each scheme into 
an equivalent in 2Gy fractions which would give the same biological effect, i.e., EDQ2. 
The equation that allows the calculation of the equivalent dose in fractions of 2Gy is 
(Eq.4) [9]: 
EDQ2 = D
𝑑+(𝛼 𝛽⁄ )
2+(𝛼 𝛽⁄ )
 (𝐸𝑞. 4) 
26 
 
Where EDQ2 represents the dose in fractions of 2Gy which is biologically equivalent to 
a total dose D with a dose per fraction d. Since EDQ2 uses doses per fraction of 2Gy, 
which are the most used in clinical practice, it has the advantage that the values obtained 
are recognized by radiotherapists [9]. 
 
2.2.4.4 Incomplete repair 
The simple LQ model states that a time interval between fractions is required to allow full 
repair of the sublethal damages occurring after each dose of radiation. This time interval 
between fractions should last for at least 6 hours, but in some cases, such as the spinal 
cord, it may last up to 1 day. If the time interval between fractions is not performed, in 
the case of several fractions per day, reparation of fractional damage may not be 
completed before the next fraction administered. If this occurs, we find that there is an 
interaction between the unrepaired residual damage of a fraction and the damage 
caused by a subsequent fraction [9]. 
When incomplete repair occurs, the dose required to produce the same biological effect 
decreases. The influence of this repair is determined by the repair interval required for 
each tissue, which consists of the time needed between fractions for which half of the 
maximum repair possible occurs. There is an adapted BED formula that considers the 
situation of the influence of incomplete repair. It is described in Annex A in the section 
"Appendix A" [9]. 
 
2.2.4.5 Time factor – repopulation 
Proliferation during radiotherapy treatment decreases the major effects of radiation. In 
late response tissues, i.e., in tissues with slow proliferation, repopulation is insignificant. 
However, in tissues with rapid proliferation, such as tumors, repopulation can lead to 
apoptosis. For tumor repopulation to occur, it is necessary to decrease the size of the 
tumor so that the cells that are in hypoxia take the place of those that are more at the 
periphery and then come into contact with the oxygen in the bloodstream [9, 28]. 
There is a formula for calculating BED considering the repopulation factor, which is 
described in Annex A in the section "Appendix A". 
In most tumors and rapidly proliferating tissues, the repopulation is about 0.5-0.8Gy. In 
general, human tumors have a doubling time of their volume ranging from 1-3 months, 
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however the cell doubling rate is 3-5 days. Prostate cancer has an extremely slow 
proliferation and its cell doubling time is, on average, 42 days [9, 28, 29].  
 
2.2.4.6 Advantages and disadvantages of BED 
The use of BED brings advantages such as the comparison of different treatment 
regimens that allows a posterior evaluation of the existing differences in clinical practice 
or previous clinical trials. In addition, BED was also used initially in animal experiments, 
which allowed the preparation of several revisions and the transposition of this concept 
into clinical practice [28]. 
In general, the practice of BED has few disadvantages, being increasingly used in 
radiobiology for comparison of fractionation schemes. A possible disadvantage is the still 
existing confusion with the biologically equivalent dose, which has long been reiterated 
as incorrect [28]. 
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Chapter 3 
 
3. The spinal cord 
3.1 Anatomy  
The nervous system is usually divided into different parts, according to structure and 
function (Figure 8). Structurally, it is divided into the central nervous system (CNS) and 
peripheral nervous system (PNS). Functionally, it is divided into somatic and visceral 
parts [34]. 
 
 
 
 
Figure 8 Constituents of the nervous system. 
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The main functions of the nervous system, which is involved in most of the organic 
functions, are [35]: 
 
▪ Sensory information, where sensory receptors monitor external and internal 
stimuli; 
▪ Integration, where the sensory information processing organs and response 
initiators, the brain and the spinal cord, produce an immediate response or store 
as memory for later use; 
▪ Homeostasis, the body's ability to present a constant characteristic physical-
chemical situation, where the central, endocrine, excretory, circulatory and 
respiratory nervous systems are immobilized; 
▪ Mental activity, where the encephalon is the centre of mental activities, including 
consciousness, thought, memory and emotions; 
▪ Control of muscles and glands. 
 
The CNS has embryonic origin being composed of the brain and the spinal cord, which 
are protected by the bones that surround them. On the other hand, the SNP is the part 
of the nervous system that is outside the CNS. It is composed of spinal and cranial 
nerves, sensory receptors, ganglia, visceral plexus and enteric system [34, 35]. 
While the CNS receives sensory information, evaluates it, stores part of it and triggers 
reactions, the SNP collects information from various sources, from the inside and outside 
of the body, and relays it through the axons to the CNS. Structural activity develops from 
the axons of motor neurons in the PNS that relay the CNS information to various parts 
of the body, especially to the glands and muscles [35]. 
The encephalon is located inside the cranial cavity and the spinal cord lies within the 
spinal canal, formed by the vertebrae. The spinal cord is in continuity with the brain 
through the occipital hole, whose function is to integrate the information received and 
produce responses through reflex mechanisms (Figure 9) [35]. 
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Structurally, the spinal cord extends from the occipital hole to the level of the second 
lumbar vertebra. This occurs because the spinal growth rate is higher than the spinal 
cord. It has an approximately cylindrical shape and in the transverse section has a 
circular/oval shape with a central canal (Figure 10) [34, 35]. 
 
 
The spinal cord extends from the foramen magnum to approximately the level of the 
intervertebral disc of the L1 and L2 vertebrae, in the case of adults. Its length may range 
and reach only D12, shorter, or reach the intervertebral disc between the longer L2 and 
L3 vertebrae. In new-borns, spinal cord extension is larger when compared to extension 
in adults, where it can reach the L3 and L4 vertebrae. The end of the spinal cord is called 
the medullary cone because it has a cone shape. A terminal filament connective tissue 
Figure 9 Constituents of the spinal cord. Adapted from [36]. 
Figure 10 Representation of different sections of the spinal cord. 
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filament extends from the apex of the medullary cone to the coccyx. This filament is 
responsible for the attachment of the spinal cord to the coccyx. The medullary cone and 
the various nerves extending downward are called the equine tail [34, 35]. 
 
 It is composed of five segments that are designated according to the area of the spine 
by which their nerves enter and leave (Figure 11) [34, 35]: 
▪ Cervical segment, eight pairs of nerves (C1 to C8); 
▪ Thoracic segment, twelve pairs of nerves (T1 to T12); 
▪ Lumbar segment, five pairs of nerves (L1 to L5); 
▪ Sacral segment, five pairs of nerves (S1 to S5); 
▪ Coccygeal segment, a pair of nerves (C0). 
 
 
 
 
Figure 11 Spinal cord: segments and their function. Adapted from [36]. 
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There are thirty-one pairs of spinal nerves that originate in the spinal cord and pass out 
of the spine through the intervertebral holes or conjugation holes. The fact that the spinal 
cord does not have a uniform diameter throughout its length, there is a decrease in the 
diameter from top to bottom, due to the presence of two dilatations, termed cervical 
dilatation and lumbar dilatation. These dilations are associated with the origin of the 
spinal nerves that innervate the upper and lower limbs. Cervical dilatation, responsible 
for the innervation of the upper limbs, occurs in the region associated with the origin of 
the spinal nerves from C5 to T1. Lumbar dilation, responsible for innervation of the lower 
limbs, occurs in the region associated with the origin of the spinal nerves L1 to S3 [34, 
35]. 
Externally, the spinal cord has several grooves and fissures, namely the median anterior 
cleft, the median posterior sulcus and the posterolateral sulcus. The latter is located on 
each side of the posterior face and represents the place where the posterior radicular of 
the spinal nerves enter the spinal cord. In the medullary structure, the grooves are deep 
crevices that partially separate the two halves of the spinal cord. About the inner surface 
of the spinal cord, it consists of a central canal surrounded by grey and white matter 
(Figure 12). 
 
 
 
 
 
Figure 12 Cross section of the spinal cord Adapted from [36]. 
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The grey matter has numerous bodies of neurons arranged in longitudinal columns along 
the spinal cord, forming an "H" figure in the cross-sectional images. It has in its 
constitution axons and dendrites. The grey matter of the spinal cord is arranged in 
anterior, lateral and posterior horns. On the other hand, the white matter surrounds the 
grey matter and contains numerous prolongations of neurons, that is, myelinated axons. 
The white matter is organized on each side of the spinal cord into three strands: anterior, 
lateral and posterior cord. In turn, each cord divides into bundles or nerve pathways that 
are responsible for transmitting information to other spinal or brain levels. The two 
substances of the spinal cord are connected through grey and white commissures. 
These have axons that cross from side to side of the spinal cord. In the centre of the grey 
commissure we can find the central canal (Figure 13) [34, 35]. 
 
 
 
 
 
 
 
 
 
 
 
The spinal nerves come from numerous radicles that lie along the dorsal and ventral 
surfaces of the spinal cord. The junction of about six to eight radicles originates each 
posterior root of the dorsal side. Each of the dorsal roots has a ganglion called the dorsal 
root ganglion, spinal ganglion and spinal ganglion [35]. 
The meninges consist of three layers of connective tissue that have the function of 
enveloping and protecting the brain and spinal cord (Table 6). 
 
Figure 13 Diagram of transverse section of spinal cord. 
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Table 6 Types of mater. Adapted from [35]. 
Types of mater 
DURA MATER  ARACHNOID MATER PIA MATER 
More superficial layer and thicker 
layer. This layer involves the spinal 
cord and is in continuity of the 
epidermis of the spinal nerves. It is 
separated from the periosteum of the 
spinal canal by the epidural space. 
This space has fat, areolar 
connective tissue and blood vessels. 
Very thin and slim layer. The space 
between this layer and the dura 
mater is called a subdural space, 
which contains a small amount of 
serous fluid. 
The pia mater layer bonds very 
closely to the surface of the brain and 
spinal cord. In this layer occurs the 
formation of the terminal filament 
beyond the medullary cone. The 
space between the arachnoid layer 
and the pia mater is called the 
subarachnoid space containing 
encephaloraquidian fluid. 
 
The last topic to mention is the vascularization of the spinal cord. The arteries that 
vascularize the spinal cord region are anterior and posterior root arteries. There are also 
segmental medullary arteries and anterior and posterior spinal arteries. The veins that 
drain the spinal cord form some longitudinal channels: two pairs of veins on each side 
supporting the connections of the anterior and posterior roots of the spinal cord, a midline 
channel that is parallel to the anterior medial cleft and a midline channel that follows 
along the posterior median sulcus [34]. 
 
3.2 Physiology 
The spinal cord represents an important role in mediating simple reflexes and in creating 
coordinated sequences of movements. According to Sten Grillner, in all vertebrates the 
spinal cord produces a basic pattern of locomotion coordination, whether it is movements 
that are required to walk, swim or fly [38]. 
The PNS contains twelve pairs of cranial nerves, in addition to the thirty-one pairs of 
existing spinal nerves. The spinal nerves are designated according to the region of their 
exit (Table 7). 
A nerve consists of nerve fibers consisting of axons of afferent neurons, afferent neurons, 
or both. Thus, the fibers of the nerves can be divided into two groups: afferent division 
or efferent division of the PNS. Afferent fibers are responsible for conducting information 
from the sensory receptors of the PNS to the CNS. 
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Table 7 Description of the functions of the different spinal nerves. Adapted from [39]. 
Spinal nerves Function 
Cervical 
Control of muscles and glands, receiving 
sensory information from the head, neck, arms 
and hands. 
Thoracic 
Innervation of the thoracic and abdominal 
walls. 
Lumbar Associated with the hip and legs. 
Sacral 
Innervation of genitals and lower digestive 
tract. 
Coccygeal Innervation of the coccyx. 
 
The efferent division is subdivided into the somatic nervous system and the autonomic 
nervous system. Somatic division neurons innervate the skeletal muscles, while 
autonomic division neurons innervate the smooth and cardiac muscles, glands and 
neurons of the gastrointestinal tract [39]. 
In the dorsal roots, from the peripheral nerves, groups of afferent nerve fibers enter the 
spinal cord. The axons of the efferent neurons leave the spinal cord through the ventral 
roots. At a small distance from the spinal cord, the dorsal and ventral roots of the same 
level join to form a spinal nerve on each side of the spinal cord [39]. 
 
3.3 Tumors in the spinal cord  
A tumor located inside or near the spinal cord can stop communication between the 
bundles, which transmit messages between the brain and nerves throughout the body 
and threaten the patient's health [40]. 
The tumors formed in this organ develop between the protective sheaths or the 
superficial sheath that lines the spinal cord. 
Most tumors that develop inside the spinal cord do not progress to other parts of the 
body being termed primary. Generally, they are benign tumors. On the other hand, 
malignant spinal cord tumors are secondary tumors, that is, they spread through the 
body from a primary cancer located elsewhere in the body. 
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Of the tumors found in the spine, 95% are not found in the spinal cord: 55% are in the 
vertebrae or in the circulating tissues outside the dura mater, and 40% are in the dura 
mater. The remaining 5% appear in the spinal cord (Figure 14). Spinal cord tumors are 
usually divided according to their location (Table 8). 
Table 8 Description of the types of tumors that may arise in the spinal cord. Adapted from [41, 42]. 
Tumor Description Visualization 
Extradural 
Proliferate outside the dura mater and 
are usually located in the vertebrae. 
They are often secondary malignant 
tumors, i.e., metastases. 
 
Intradural extramedullary 
They develop within the dura, outside 
the spinal cord. Usually, these tumors 
are benign and proliferate slowly. 
Most of these spinal tumors are: 
meningiomas (occurring in the 
membranes that surround the spinal 
cord and are usually benign but may 
be malignant, tumors are more 
common in middle age and in older 
women) and tumors in the nerve 
sheath. 
 
Intramedullary 
They grow inside the spinal cord. 
They are often benign primary tumors. 
 
Figure 14 Representative scheme of the type of tumors in the vertebral column. 
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3.4 Complications after irradiation in the spinal cord 
The spinal cord is the most dose-limiting organ in radiation therapy. In this organ, 
radiation-induced lesions can result in devastating functional deficits that may manifest 
in months or years after radiotherapy treatment [5]. 
Advances in biology, physics and radiotherapy have led to an evolution in the treatment 
of tumors and consequently survival rates have increased for a wide variety of 
malignancies. 
However, this increase in survival has consequences that need to be considered. 
Patients who have already suffered from a malignant disease are at increased risk of 
developing a second neoplasm. There are three main reasons for this [9]. 
1) When comparing individuals with the same lifestyle, age, gender, and other 
characteristics, we can observe that patients with a history of neoplastic disease 
are at greater risk of developing a second neoplasm; 
2) The etiological factors, related to the first tumor, can remain active and promote 
the evolution of a second neoplasm; 
3) The therapies used to combat the first tumor, namely chemotherapy and 
radiotherapy, are associated with an increased risk of developing second 
neoplasms. 
In addressing the issue of irradiation of normal tissues it is necessary to consider account 
two concepts: acute toxicity and late toxicity. Acute toxicity affects proliferative and 
repairing tissues such as the epidermis and mucous membranes. Damage repair is 
performed using surviving stem cells that are within the irradiated volume or based on 
the stem cells that migrate from the non-irradiated sites to the irradiated sites. These 
cells allow regeneration and restoration of tissues and cells resulting in complete or 
partial restoration of radiation tolerance [9]. 
Despite the advances made, acute toxicity continues to have a significant effect on 
patients' quality of life. Some of the acute responses from radiation therapy are dose 
limiting, such as oral mucositis in advanced head and neck tumor radiotherapy [9]. 
On the other hand, late toxicity results in parenchymal damage that may lead to eventual 
loss of function within the irradiated volume. The clinical consequences of irradiation 
depend on the organ architecture and irradiated volume. It is essential to note that the 
radiosensitivity of a single cellular component cannot be used as a predictor of organ 
sensitivity. In the case of re-irradiation, for palliative purposes, late toxicity may not 
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become clinically apparent during the limited life span of most patients. In the case of re-
irradiation, it is necessary to evaluate the biologically effective dose (BED) and the 
delayed effects that come from the previous treatment, and it is necessary to exclude 
the patients who tolerated the previous treatment [6, 9].  
It is necessary to take into consideration the irradiation of the spinal cord when irradiating 
areas such as the abdomen, pelvis and in cases of bone metastasis in the spine, this 
occurs in about 40% of the patients with cancer [43]. 
Several authors described the effects felt in the spinal cord after irradiation, although the 
definitions and concepts may differ between them. According to Rega et al., one of the 
complications of the spinal cord is radiogenic myelitis that can be defined as exclusively 
chronic radiogenic myelopathy syndrome. This syndrome manifests itself between 9 and 
15 months and may also manifest up to 3 years after irradiation and is associated with 
symptoms such as paraesthesia, sensory disorders and, sometimes, dysfunctions in the 
bladder and intestine with late development [44, 45].  
There are several clinical syndromes of radiogenic myelopathy: 
▪ The most common myelopathy, which is not associated with any other 
abnormality in the neurological examination, is characterized by the presence of 
the Lhermitte's signal. This signal consists of a sensation of shocks that travel 
through the cervical and thoracic segments of the spinal cord with irradiation to 
the upper limbs and sometimes to the lower limbs when the patient performs 
flexion of the cervical spine [43]; Acute transient radiogenic myelopathy occurs 
most commonly in the cervical and thoracic segments of the spinal cord, and it is 
estimated that approximately 15% of patients with mantle irradiation in Hodgkin's 
disease develop this syndrome. Transient demyelination occurs due to a lesion 
in the oligodendrocytes. These cells are responsible for the formation and 
maintenance of the myelin sheaths of the CNS axons [44, 45]; 
▪ A possible syndrome is secondary to a spinal cord injury caused by damage to 
the blood vessels caused by radiation [44, 45]; 
▪ The third syndrome results, presumably from selective damage to the anterior 
horn of the grey matter, and this part of the bone marrow contains motor neurons 
responsible for axial movements [44, 45]; 
▪ Finally, chronic radiogenic progressive myelopathy where pathological findings 
have been described and is associated with permanent signs that are caused by 
vascular damage and damage to oligodendrocytes. These damages result in 
necrosis of the white matter or in demyelination. However, there are patients who 
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stabilize after a partial neurological loss, this event is called Brown-Sequard 
Syndrome, characterized by a classic presentation that combines sensory motor 
and tactile deficits, vibration, sensory deficits of the joint position on one side of 
the body and sensory deficits in temperature and pain on the contralateral side. 
This syndrome is most commonly referred to in radio-oncology. It is progressive 
and permanent and often leads to fatal complications such as an infection or 
pulmonary embolism. Chronic progressive myelopathy has associated risk 
factors such as: the total dose and dose per fraction administered, the volume 
and segment of the spinal cord irradiated and the re-irradiation of the marrow for 
the control of the malignant disease. All these factors have an indefinite relative 
influence regarding the dose given incidentally to the spinal cord, when treating 
tumors in their anatomic region [44, 45]. 
Spinal haemorrhage is also a late complication that can occur in the spinal cord after its 
irradiation. It can occur 6 to 30 years after its irradiation, being rarely reported. It develops 
within irradiated sites, but outside the location of the primary tumor. The symptoms that 
the patients initially present are: weakness in the lower limbs and painful complaints in 
the back. These symptoms progress rapidly to paresis and tetraparesis. Telangiectasias 
caused by radiation are the probable cause of these haemorrhages [44]. 
The lesions that occur in the spinal cord are divided into three groups (Table 9). 
Table 9 Lesions in the spinal cord appear in different ways after irradiation. Adapted from: [46]. 
Lesions in the spinal cord Description  
Early  There are no record of acute central nervous system (CNS) syndrome after large 
single doses to the cord. Clinically, it was found that the damage that occurred is 
generally related to increased tumor edema as in the context of extradural cord 
compression. 
Early delayed  L’hermitte syndrome is observed after doses well below the threshold of myelopathy, 
and it is not associated with permanent myelopathy. this state occurs after a latent 
period of 2 to 4 months and is characterized by paraesthesia in the back and 
extremities upon neck flexion typically, followed by complete clinical recovery after a 
few months. It is characterized by an electrical sensation that runs down the back and 
into the limbs. The sensation can feel like it goes up or down the spine and it is 
uncomfortable for the patient. 
Late  RM is a typical late affect. This disease is normally irreversible. After the diagnosis of 
permanent myelopathy, the median survival of the patients was 8 months. The latent 
time after a single treatment was 18 months and after re-irradiation was 11 months. 
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3.5 Spinal cord doses and tolerance  
As previously mentioned, there are several factors that are associated with the 
development of radiogenic myelopathy. These factors combined with the remaining 
complications associated with spinal cord irradiation are profoundly related to the 
tolerance of this organ to radiation. 
Tolerance is an essential concept when treating radiotherapy because only through its 
knowledge can it be possible to plan treatments that do not compromise the integrity of 
healthy organs and allow the lowest risk of complications. 
The dose of radiation that can be delivered for tumor control is limited by late and 
generally irreversible injury of the surrounding normal tissues and organs at risk (OAR), 
also known as late effects. 
The spinal cord is the most critical organ at risk. It is typically located near the vertebral 
tumor target volume and has been classically described as an organ with a serial 
functional architecture and as such damage to small volumes within the structure can 
have a major impact on neurologic function [47].  
As a result of greater accuracy and effectiveness of cancer treatment, patient survival 
rates increase, and radiation oncologists are frequently faced with the problem of 
treatment of local recurrence or second tumors located within or close to previously 
treated sites [32].  
Radiation myelopathy is one of the most devastating complications of clinical 
radiotherapy resulting in severe and irreversible morbidity. Assessment of the impact of 
dose and fractionation schemes on tissue tolerance has been a major area of research 
in radiation oncology. 
A comprehensive set of dose tolerance limits for normal tissue to RT became a reference 
landmark in radiation oncology [48]. In an extensive review of spinal cord re-irradiation, 
it was concluded that a dose of 50Gy in the spinal cord causes a risk of myelopathy of 
0.2%. If the dose increases to 59Gy the risk of myelopathy increases to 5% [45, 49].  
There is consensus regarding the dose of tolerance accepted in the spinal cord that with 
conventional fractionation of 2Gy per day including the full cord cross-section, a total 
dose of 50Gy, 60Gy and 69Gy is associated with a 0.2, 6 and 50% rate of myelopathy 
[50].  
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As a result, standard RT involving spinal cord treatment delivers a maximum dose of 
50Gy with conventional fractionation 1.8-2Gy per fraction. Data obtained experimentally 
indicates that dose reduction per fraction below 2Gy does not significantly alter the 
absolute dose-response [45]. 
 
3.6 Radiobiology of the spinal cord 
The various outcomes associated with spinal cord irradiation are vascular damage, 
radiogenic myelopathy and white matter necrosis. The main factors related to the 
development of myelopathy are related to [9, 29, 45, 51]: 
▪ Total administered dose; 
▪ Dose per fraction; 
▪ Volume and irradiated segment of the spinal cord; 
▪ Re-irradiation of the spinal cord due to the need to control tumor disease; 
▪ Variability of radiation sensitivity between different patients. 
When the location of the tumor is very close to a critical organ, such as the spinal cord, 
the dose it receives will not be homogenous throughout its length. Although this situation 
is recurrent, the influence of inhomogeneous distribution on bone marrow tolerance is 
not known. This is because existing data describing the dose-response relationship and 
dose-volume effects of the central nervous system are based on animal experiments 
following homogenous spinal cord irradiation [52, 53]. 
In rats, the grey matter does not present any damages with doses up to 80Gy. On the 
other hand, the white matter in the left lateral half of the cervical cord was more sensitive 
than the white substance located in the middle. Necrosis of the white matter results in 
paralysis [53]. 
There is a difference in radiosensitivity between the grey and white matter that probably 
originates from the anatomical and physiological differences in the different parts of the 
spinal cord, since the supply and vascular density are distinct in these two areas. 
Regionally, vascular density is greater in the grey matter than in the white matter, being 
greater in the ventral half than in the dorsal half of the grey matter. The proportion of 
blood flow from the grey matter to the white matter is 3:1. The blood flow of the white 
matter has a non-homogeneous pattern and the grey matter pattern is more variable. 
Thus, the regional difference in white matter radiosensitivity is not only associated with 
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vascular damage because there is no regional difference in vascular density or blood 
flow [43, 53]. 
The grey matter consists mostly of whole cells, while the white matter contains axons 
and myelin sheaths. The myelin sheaths have an insulating function, in a purely 
speculative way, it can be said that this structure can be damaged by radiation and thus 
conclude that the white matter is more radiosensitive. Along the extension of the spinal 
cord the amount of white matter decreases because there are fewer axons. Therefore, 
the greater sensitivity of the white matter may be associated with the presence of 
Schwann cells, which accumulate myelin, allowing to conclude that a spinal region is 
more sensitive the greater the amount of white matter [51]. 
Although a matter of great importance, radiosensitivity of the spinal cord was, until a few 
years ago, a subject ignored by radiation oncologists. A non-significant part of radiation 
oncologists considered the different doses of tolerance along the spinal cord and the 
effect of volume also did not reveal a major weight in medical treatment decisions. A 
reason for this fact is related to the scarcity of clinical data on the subject in 1998 [54].  
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Chapter 4 
 
4. Re-irradiation 
Due to the increased survival rate of patients with multiple tumors, there are a greater 
number of cases where radiation oncologists are faced with the need to treat late 
recurrences or second tumors. Radiotherapy is one of the possible treatments to combat 
second primary tumors or recurrences and, for this, it is necessary to consider certain 
parameters in the decision making of a re-irradiation. This decision becomes complicated 
because these recurrences and new tumors are located within or near the previously 
treated region. Tolerance doses of adjacent organs cause concern and need special 
attention. The tolerance dose of normal tissues is significantly reduced in re-irradiation 
when compared to that of the first treatment [5, 6]. 
When assessing tumor re-irradiation, it is necessary to consider whether the dose of 
tolerance of an organ has already been reached in the first course of treatment. Treating 
an area that had prior radiation is far more complex than the initial treatment. 
When tissue tolerance is not achieved and only induction of subclinical or minimal 
damage occurs in the long-term recovery or induction of residual damage with 
manifestation after long years, re-irradiation may be considered. Re-irradiation has a 
curative and palliative purpose. In case of re-irradiation with curative intent it is necessary 
to evaluate the biologically effective dose and the late effects of the initial treatment. On 
the other hand, in the palliative re-irradiation the late toxicity felt may not manifest during 
the limited life of the patient [6, 9]. 
In re-irradiation it is of extreme interest to consider the knowledge about the kinetics of 
the evolution of the hidden damages caused by the previous treatment. Key re-irradiation 
parameters evaluated in the decision process include [5, 55]: 
▪ Data from previous treatment such as irradiated spinal cord volume and region; 
▪ Total dose; 
▪ Dose per fraction administered; 
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▪ Time elapsed since the first treatment; 
▪ Additional treatments for the first tumor (e.g. chemotherapy, ‘biologicals’); 
▪ Organs and tissues involved; 
▪ Alternative treatment options. 
Over the years the treatment administration has become more accurate and safer due 
to the appearance of equipment and techniques, and an evolution of radiation oncology 
has been observed. The possibility of performing a re-irradiation treatment, where the 
organs of risk can receive high cumulative doses of radiation, appear due to new 
knowledge in radiotherapy that allow the approach of new possibilities of treatment [6]. 
Despite the remarkable development in RT, it is necessary to consider the clinical side 
effects that may result from a re-irradiation. It is essential to give importance to certain 
aspects such as: the possibility of disease progression in other parts of the body, the 
general state of the patient, the acute and late toxicities caused by the treatment, as well 
as the quality of life of the patient [6]. 
Many radiation oncologists rejected re-irradiation for curative purposes, after a radical 
radiotherapy treatment, due to the complications inherent in this type of treatment. In the 
literature, several studies began to emerge with experimental data indicating the 
recovery capacity of previously caused damages of some tissues. Radiation oncologists, 
being aware of these studies, remained reluctant to re-irradiate patients who had 
previously received high doses. This reluctance prevented re-irradiation for the curative 
and palliative purposes of some patients [55]. 
There are two factors that benefit the re-irradiation process [56]: 
▪ Low doses administered on the first treatment; 
▪ Long-time interval between treatments. 
 
4.1 Re-irradiation of spinal cord 
The spinal cord is the most critical organ at risk (OAR). This organ is typically located 
near the vertebral tumour target volume and has been classically described as an organ 
with a serial functional architecture and as such damage to small volumes within the 
structure can have a major impact on neurologic function [47]. 
Myelopathy is a devastating late-effect of radiation therapy, and the spinal cord is 
considered one of the most critical dose-limiting organs. For this reason, radiation-
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induced myelopathy is one of the most feared complications associated with SBRT given 
that patients may become paralyzed and even die [40, 46, 57, 58]. 
When the spinal cord is within the target volume, physicians choose for more 
conservative treatments since radiogenic myelopathy is a problematic late consequence. 
However, this greater conservatism at the time of the treatment may result in a dose to 
the sub-optimal tumor which will give rise to a reduced probability of tumor control. In 
several clinical cases it is necessary to consider if a higher dose in the tumor 
compensates the increased risk of developing myelopathy. There are rare situations 
where the development of this pathology occurs below a dose of 45Gy, this fact is due 
to three factors [5, 32, 45]: 
1) Extrinsic factors, which reduce radiation tolerance in some individuals; 
2) Thousands of people are irradiated annually with this dose, which increases the 
probability of occurrence of these rarer situations; 
3) Actual doses given are higher than the estimated doses. 
Re-treatment in periods shorter than two years may increase the risk of developing 
complications, since they are more likely to express themselves during this time period 
[45]. 
For a total dose of 34Gy to the spinal cord, it is estimated that after 1 year recovery is 
76%. For a total dose of 38Gy it is estimated that after 2 years, a recovery of 85% occurs 
[43]. 
Initial dose influences different time intervals from tissue tolerance to re-irradiation as 
well as conditioning the recovery of radiation damage in the first treatment. It is possible 
to administer a higher dose in the re-irradiation if smaller doses were used at the first 
treatment and if the intervals between treatments were longer [5, 32].  
The occurrence of myelopathy should not be reduced by the limitation imposed on the 
total doses administered. This reduction should result from determining factors such as: 
the patient's physical state and the average history, which give rise to a greater 
radiosensitivity of the spinal cord. If this is justified, the risk of developing myelopathy 
may be overlap by a significantly greater hypothesis of tumor control [45, 56]. 
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4.1.1 Time interval between fractions / total treatment time 
All decisions regarding re-treatment of the spinal cord have been performed to date, 
based on empirical data. However, in the experimental literature there are several 
evidences that corroborate the capacity of recovery of the spinal cord depends on the 
time elapsed between the two treatments. Although there is evidence that proves the 
recovery of the spinal cord, there are still some controversies in the transformation of 
experimental data obtained in animals for clinical situations. These controversies stem 
from the differences between the two groups of living beings [32]. 
In fractional schemes with multiple daily fractions it is essential to create a break between 
fractions as long as possible. Due to the catastrophic effect of radiogenic myelopathy, 
repair of sublethal damage in the spinal cord may not be complete after an interval of 8 
hours. The kinetics of repair of the spinal cord is slower, so it is not advantageous to use 
schemes with interfraction intervals of less than 6 hours. When the tissue repair interval 
exceeds 4 hours, even doubling the interval time, i.e., 8 hours, there will still be no 
amount of damage that has not been repaired [32]. 
A significant recovery of the long-term damage was shown to occur in the rat spinal cord. 
The tolerance of the organ to the re-irradiation was influenced by the level of initial 
damages, as well as, the time of expression of the damages occurred (latency time). 
Thus, increasing the time interval between treatments results in an increase in recovery 
from damage and, consequently, a recovery of what is generally estimated, leading to 
prescribed doses in re-treatment that are lower than necessary [5,32, 43].  
It was demonstrated that the latency time for paralysis increases with the increase in the 
time interval between initial treatment and re-irradiation, decreasing with increasing of 
the damage. The latency time for myelopathy decreases after the required re-irradiation 
[5, 32]. 
Time of recovery from damage depends on the tissue or species, as well as on the age 
of the individual: In animal experiments performed it was observed that 3-week-old mice 
showed effects faster than adult mice. However, long-term recovery occurred more 
rapidly in younger rats (3 weeks old) [32, 43]. 
Long-term recovery was observed after 8 weeks and it increased with time interval to re-
treatment. The initial dose influenced tolerance to re-treatment and radiation damage 
repair at different intervals with long-term recovery after 6 months being approximately 
45% [5, 32].  
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This evidence shows that, the younger, immature spinal cords are slightly more 
susceptible to radiation and have a shorter latency period. Thus, special care is required 
in spinal cord irradiation in pediatric situations because of the increased sensitivity of the 
child to radiation because their CNS and skeleton are in development [43]. 
In conclusion: re-treatment in periods shorter than two years may increase the risk of 
developing complications, since lesions are more likely to develop during this time period 
[43]. Nevertheless, when the time interval between the first treatment and the re-
treatment is less than 6 months; the biologically effective dose of each treatment is less 
of 98Gy2, no cases of radiation myelopathy where observed when cumulative BED is 
≤120Gy2 [31]. 
 
4.1.2 Fractionation 
During the 20th century, radiobiological investigation revealed that fractionation of a dose 
of radiation often produces better tumor control for a certain level of toxicity of normal 
tissues. Adopting dose fractionation, instead of administering the total dose of radiation 
in a single fraction, better preservation of normal tissues is achieved which may result 
from repair of sublethal damage between fractions. The emergence of new alternative 
fractionation schemes in clinical radiotherapy, which lead to the development of new 
treatment strategies, results from radiobiological research and clinical observations 
(Table 10) [6, 32]. 
Table 10 Different types of fractionation schemes and their description. Adapted from: [7]. 
Types of fractionation Dose per fraction Time of administration Weekly dose 
Accelerated 1.8–2.0Gy/day More than 1 fraction/day – 
Conventional 1.8–2.0Gy/day 5 days/week 9.0–10.0Gy 
Hyperfractionation < 2.0Gy/day 
2 fractions/day, with 
interval of 6–8 hours 
– 
Hypofractionation > 2.0Gy/day < 5 days/week – 
Continuous accelerated 
hyperfractionated 
radiotherapy (CHART) 
– 
3 fractions/day, during 12 
days with intervals 
between fractions of 6 
hours 
– 
 
The fractionation schemes that administer more than a daily fraction are: 
hyperfractionation and accelerated fractionation, in which in these types of fractionation 
the interval of time interferes changes the 24 hours for a range of 3 to hours, depending 
on the scheme used. Thus, a devaluation of the benefit of the treatment may occur since 
50 
 
the achieved tumor control does not compensate for the exceeded tolerance dose of the 
tissues. This excess tolerance dose originates from the incomplete repair of damage 
between fractions [32]. 
When radiotherapy is administered for curative purposes, there is a greater risk of 
developing lesions in normal tissues. Thus, it is necessary to know the rate of repair of 
the tissues to later select the time interval between fractions and the most appropriate 
fractionation. The rate of tumor control depends on the tolerance of normal tissues to 
radiation. Clinical data on spinal cord tolerances to re-irradiation are rare and generally 
come from reports of limited cases [32].  
It is possible to conclude that initial doses influence [5]: 
▪ Different time intervals from tissue tolerance to re-irradiation; 
▪ Recovery of induced damage in the first treatment. 
It is possible to administer a higher dose in the re-irradiation if smaller doses were used 
at the first treatment and if the intervals between treatments were longer [5, 32]. 
To obtain a better fractionation scheme it is important to obtain radiobiological data with 
the purpose of confirming or refuting the biological models. If excessive risk factors are 
controlled, it is possible to maintain the level of development of myelopathies at a 
minimum, making the doses prescribed to tumor volume the most appropriate for the 
disease [32]. 
 
4.2 Stereotactic body radiotherapy (SBRT) 
Initially, this technique was developed for the treatment of spinal metastases when the 
clinical setting was a re-irradiation. However, it is currently an emerging treatment option 
for vertebral metastases with proven efficacy in the initial, post-operative, re-treatment, 
and for tumors with radioresistant histology [47, 59, 60]. 
SBRT is a new method of treatment in radiotherapy, which provides a high dose of high 
radiation to small and well-defined targets with a single or a few fractions with a high 
degree of precision inside the patient's body. This type of therapeutic protocol is called 
hypofractionation of radiotherapy and is characterized by its high biological efficacy, with 
favourable clinical results about tumor control and the rate of late complications [58]. 
SBRT uses radiation doses in a few fractions, usually 1 to 5, for the target, thus, spinal 
cord tumors are treated with high biologically effective doses (BED).  
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According to the American College of Radiology (ACR) and the American Society for 
Radiation Oncology (ASTRO), SBRT is define as “an external beam radiation therapy 
method used to very precisely deliver a high dose of radiation to an extracranial target 
within the body, using either a single dose or a small number of fractions.” [61]. 
More and more cancer patients are treated with SBRT. The change from conventional 
fractionated radiotherapy to hypofractionated SBRT is due to technological advances in 
tumor imaging and radiation delivery systems [62]. 
This treatment involves a high level of precision, accuracy and reproducibility throughout 
the treatment process. To deliver radiation only at the target volume, it is necessary to 
minimize the margins for dose delivery. For this, the location of the target volume and its 
movement is limited. Patient immobilization systems must be very accurate, and the 
radiation equipment must have a mechanical tolerance for emission of +/- 2mm [58, 63]. 
In the case of the IPO-PORTO, this mechanical tolerance for emission is less than 1mm. 
To minimize normal tissue toxicity, conformation of high target doses, and rapid dose 
drop gradients off the target, are obtained through multiple coplanar, non-coplanar static 
fields or arc therapy [58]. 
Flattening filter free (FFF) linear accelerators allow for an increase in instantaneous 
dose-rate of the x-ray pulses by a factor of 2–6 over the conventional flattened output As 
a result, radiobiological investigations are being carried out to determine the effect of 
these higher dose-rates on cell response [64]. The studies reported thus far have 
presented conflicting results, with some suggesting that increasing dose rate is an 
acceptable manner of decreasing radiotherapy treatment time that does not have any 
detrimental radiobiological effects [65]. 
Compared to conventional fractional radiotherapy, where large volumes of normal 
tissues are irradiated, the main goal of SBRT is to reach the tumor, avoiding irradiation 
of adjacent normal tissue (Figure 15). SBRT has specific characteristics that differentiate 
it from conventional RT [58, 66]: 
▪ Treatment scheme, where dose delivery is performed in one or a up to 5 fractions, 
resulting in a high BED value. In several studies, we can verify that a re-irradiation 
performed with a SBRT treatment has higher BED values when compared to the 
first conventional radiotherapy treatment (Table 11); 
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Table 11 Variation in BED value according to treatment schedule. 
 Initial treatment Re-irradiation treatment 
Author α/β value 
Dose fx(Gy)/no 
fx 
BED 
Dose fx(Gy)/no 
fx 
BED 
Grosu et al. [67] 2 
1.25/32 65.0 1.8/16 55.1 
1.4/20 49.4 3.0/10 75.0 
Wright et al. [68] 
4 3.0/10 53.0 6/5 26.0 
4 3.0/15 79.0 6/5 15.0 
2 3.0/11 83.0 6/5 20.0 
Sahgal et al. [40] 2 
1.8/30 102.6 8.0/3 120.0 
0.9/28 36.5 10.5/2 131.3 
2.88/15 105.4 16.0/1 144.0 
 
▪ Small irradiated volumes;  
▪ Inhomogeneous dose distribution (the inherent sensitivity of the dose distribution 
secondary to the steep dose gradient beyond the target volume); 
▪ Short treatment time (in a conventional treatment since the duration of the 
treatment would last for several months). 
In the limits defined by Emami [48, 49] all prescriptions were in 1.8 or 2Gy fractions. In 
contrast, SBRT prescription schemes typically range from 5Gy per fraction up to 20Gy 
per fraction or more. In this new radiation delivery paradigm, normal organ dose 
tolerance limits and the dose‐volume response of the tumors depend strongly on the 
number of fractions used and the dose per fraction. 
Figure 15 Example of contour of the spinal cord. (Images provided by the Medical Physics Service of the IPO-
Porto). 
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After more than 20 years of Radiation Therapy Oncology Group (RTOG) trials, 
conventional radiation therapy had progressed to the point where it is possible to define 
dose tolerance limits in terms of 5% or 50% chance of a specified adverse event 
occurring within five years. In contrast, published follow‐up data for SBRT is inadequate 
to reliably determine the probability of adverse events [63]. 
 
4.2.1 Late effects 
The occurrence of normal tissue damage may be associated with the amount of dose 
that is delivered in each fraction, the duration of treatment, the areas of the nervous 
system that are irradiated, the total radiation received by the patient and the patient's 
susceptibility to radiation. Symptoms of these damages can manifest themselves in the 
first days of the treatment, called early effects, or months after the last irradiation, late 
effects [66]. 
When compared to conventional fractional radiotherapy, hypofractionation, used in 
SBRT, is more likely to cause late effects, i.e., late radiation injury. 
Late effects in adjacent normal tissues are more difficult to treat when compared to early 
effects. Late vascular injury can make tissues less viable, having a low blood supply, 
poor healing, poor functional capacity and lead to necrosis, resulting in problems such 
as fistulas and ulcers, which can be debilitating and even deadly [66]. 
Hypofractionation, in 1980’s and 1990’s, was not accepted as a form of radiotherapy 
treatment, since it was proved that it caused more delayed effects than conventional 
fractionation, when the same total dose was administered. Thus, only patients with a 
very limited life span were treated with hypofractionation, as it was believed that they 
would not live long enough to present long-term effects [66]. 
Advances in biology and physics have allowed increased precision and accuracy in 
radiotherapy in order to maximize tumor damage and to minimize lesions in the dose 
limiting adjacent normal tissues. This led to an evolution in the treatment of tumors and 
consequently survival rates have been increasing for a wide variety of malignancies. 
Spine SBRT, also known as spine stereotactic radiosurgery (SRS), is an emerging 
treatment option for patients with spinal bone metastases with or without a soft tissue 
component and is rapidly being adopted in the clinical although with limited high-quality 
evidence [47, 63]. 
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SBRT is a highly effective treatment able to deliver ablative doses to tumors with minimal 
doses to the surrounding normal tissues. It Is defined as radiotherapy treatment of 
tumors outside the brain with 1 to 5 dose fractions. It has been made possible in recent 
years due to advances in image guidance, target visualization and radiation delivery 
methods that allow large doses delivered to the target while sparing critical organs at risk 
(OARs). 
Outstanding results already have led to the suggestion that high doses per fraction may 
have greater efficacy than conventional fractionated radiation therapy [25]. Local control 
rates in spine re-irradiation with SBRT reported in the literature range from 66% to 
92% at 1 year [70]. 
Initially, this technique was used to successfully palliate spinal metastases, even for 
tumors of radio-resistant histologies. This success with spinal metastases has led to the 
widespread extrapolation of SRS to the treatment of primary spine tumors and for benign 
tumors of the spinal cord [47, 59]. 
Radiation myelopathy (RM) is a late effect of radiation treatment delivered to the spinal 
cord. It is a diagnosis of exclusion, based on neurologic signs and symptoms consistent 
with damage to the irradiated segment of the spinal. This disease is a relatively rare 
disorder characterized by white matter lesions of the spinal cord resulting from 
irradiation. The observed clinical effects may be related to sensory and/or motor deficits 
to complete paraplegia/quadriplegia and loss of autonomic functioning (Figure 16) [47]. 
 
 
 
 
 
 
 
 
 
 
Figure 16 Level of lesion and extension of paralysis according to the spinal segment. 
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Myelopathy is a late complication and many patients may not have had enough time to 
manifest it. The risk of radiation myelopathy from spine SBRT has been estimated to be 
<1% [43]. 
RM is a rare late toxicity effect in the modern era of 3-dimensional conformal 
conventionally fractionated RT. This devastating late effect has re-emerged as a direct 
result of SBRT practice, where high-dose radiation is delivered adjacent to the spinal 
cord to be spared. Possible reasons include [57]: 
I. Lack of understanding of tolerance to the spinal cord with high dose per fraction 
radiation therapy; 
II. Sensitivity of the spinal cord in SBRT dose distribution to small intrafraction 
motions where even 1- to 2mm shifts during treatment can increase the actual 
spinal cord dose delivered; 
III. An assumption that a small point volume within the spinal cord can tolerate a 
higher dose of radiation than would traditionally be considered safe. 
Nieder et al. [31], developed a criteria for select patients at risk of developing myelopathy 
from 3 criteria: Cumulative BED in Gy2, interval between first treatment and re-treatment 
is < 6 months and BED value in the first treatment is >102Gy2. 
From these data we can group the patients into three different groups: low-risk, 
intermediate-risk and high-risk groups. If the patient gets less than 3 points belongs to 
the low risk group, if he has 4 to 6 points belongs to the intermediate risk group, and 
finally if he has more than 6 points belongs to the group of high risk of developing 
myelopathy (Table 12). 
 
Table 12 Risk of developing myelopathy from the characteristics mentioned in the table. Adapted from [31]. 
Points 
Cumulative BED in Gy2 with interval < 6 months and a BED of 1 
course ≥102 Gy2 
Risk of developing 
myelopathy 
0 ≤ 120.0 
Low risk 
1 120.1 – 130.0 
2 130.1 – 140.0 
3 140.1 – 150.0 
4 150.1 – 160.0 x (4.5) x (4.5) 
Intermediate risk 5 160.1 – 170.0 
6 170.1 – 180.0 
7 180.1 – 190.0 
High risk 8 190.1 – 200.0 
9 > 200.0 
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A bibliographic search was conducted in PubMed, Medline, among others, to identify 
articles with references of SBRT in cases of re-irradiation and the effect of different 
dose/fractionation regimes. Table 13 presents information regarding 1st treatment and 
re-irradiation data from several studies. Also included are values regarding: 
▪ Total dose and the number of fractions delivered, both in the initial treatment and 
in the re-treatment; 
▪ Time elapsed between the end of the first treatment and the re-treatment; 
▪ 𝛼 𝛽⁄   ratio; 
▪ Treatment area (cervical, thoracic, lumbar and sacral); 
▪ Follow-up time; 
▪ Time until radiation myelopathy appears, should it occur. 
Based on the classification developed by Nieder et al., (Table 13): when the interval 
between the two treatment courses is not shorter than 6 months and the dose of each 
course is BED ≤98Gy2, the cumulative BED where no case of radiation myelopathy (RM) 
has been reported is 120Gy2; for values between 120 and 135 Gy2, the risk of RM is 
small [31]. 
Analyzing table 13 it is possible to highlight the following: 
▪ Data presented by Wong et al. [71]: patient received 20.6Gy in the 1st treatment 
in 6 fractions and was retreated after 4 months. 
BED for 2nd treatment was 102.65Gy2; cumulative BED was 158.58Gy2. His risk 
score was 4, which presented an intermediate risk of developing myelopathy, 
which occurred after 6 months; 
▪ Data presented by Schiff et al. [72], Grosu et al. [67], Nieder et al. [31] and 
Maranzano et al. [73]: the cases reported had a time interval between treatments 
of more than 6 months, BED is ≤ 98Gy2 for each treatment, cumulative BED = 
120Gy2 and no cases of myelopathy; 
▪ Data presented by Sahgal et al. [40]: patient had a time interval between 
treatments of 5 months; cumulative BED= 204.4Gy2 and a high risk of developing 
myelopathy (score of 9). The follow-up time was very short (4 months) for the 
manifestation of symptoms, should they occur; 
▪ Data presented by Sahgal et al. [57]: 9 cases of patients developing myelopathy 
were reported. BED values ranged from 181.3 to 337.5 for the re-treatment. Time 
to manifestation of symptoms in this group of patients ranged from 3 to 15 
months. 
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Table 13 Summary of published reports of treatments performed using re-irradiation. 
 1st treatment  Re-irradiation  
Author Sample Total 
dose (Gy) 
Dose fx 
(Gy)/no fx 
Interval 
(months) 
Total dose 
(Gy) 
Dose fx 
(Gy)/no fx 
Nivel 
treated 
Value of 
α/β (Gy) 
Initial 
BED 
Irradiation 
BED 
Total 
BED 
Follow-up 
(months) 
Time to 
myelopathy 
(months) 
Wong et 
al., 1994 
[71] 
11 
2.0+45.9 2.0/1+3.06/15 12 23.6 2.36/10 T 
2 
120.13 51.45 171.58 
≥60 
4 
23.5+18.2 2.35/10+3.64/5 19 13.6 2.72/5 T 102.44 32.096 134.54 16 
20.6 3.43/6 4 36.4 3.64/10 T 55.93 102.65 158.58 6 
20.1 1.26/16 48 
14.3+3.2 
+22.6+2.57 
2.38/6+1.6/2+ 
3.76/6+2.57/1 
T 33.25 108.04 141.29 11 
16.0 3.2/5 57 22.0 7.33/3 T 41.60 102.63 144.23 7 
24.0+24.0 3.0/8+1.5/16 45 18.1 1.81/10 T 102.00 34.48 136.48 13 
20.4+20.3 4.08/5+4.06/5 10 8.2 8.2/1 T 123.53 41.82 165.35 4 
24.4 4.88/5 2 17.0 3.4/5 T 83.94 45.9 129.84 14 
31.2 1.56/20 71 30.3 5.05/6 C 55.54 106.81 162.35 25 
33.9 3.39/10 2 25.6 2.56/10 T 91.36 58.9 150.4 13 
50.0 2.5/20 27 10.4 1.04/10 T 112.50 15.81 128.31 11 
Schiff et 
al.,1995 
[72] 
54 
30.0 3.0/10 Median 9.1 
(range: 1-
51.3) 
30.6 1.8/17 T 
3 
60.0 48.96 108.96 
4.2 No cases 30.0 3.3/9 39.6 1.8/22 L 63.0 63.36 126.36 
30.0 3.0/10 22.0 2.0/11 C/T 60.0 36.7 96.7 
Sminia et 
al., 2002 
[56] 
8 
16.0 8.0/2 52 20.0 4.0/5 T 
2 
80.0 60.0 140.0 
1-54 No cases 
39.0 3.0/13 12 21.0 3.0/7 T 97.5 52.2 149.7 
8.0 8.0/1 4 18.0 3.0/6 C 40.0 45.0 125.0 
49.6 1.6/31 61 50.0 2.0/25 L 69.4 75.0 144.4 
37.4 2.2/17 30 21.0 3.0/7 T 78.5 52.2 130.7 
24.0 3.0/8 20 21.0 3.0/7 T 60.0 52.2 164.4 
25.0 1.7/15 150 16.0 4.0/4 T 46.0 48.0 142.0 
35.25 1.5/23.5 73 30.0 3.0/10 L 48.5 52.5 125.0 
Grosu et 
al., 2002 
[67] 
8 
40.0 1.25/32 
Median 
30 
(range: 6-
63) 
29.0 1.8/16 T 
2 
65.0 55.1 120.1 
Median 16 
(range: 5-
44) 
No cases 
30.0 3.0/10 30.0 2.0/15 L 75.0 60.0 135.0 
40.0 2.5/16 30.6 1.8/17 T/L 90.0 58.1 148.1 
40.0 2.0/20 30.6 1.8/17 T 80.0 58.1 138.1 
50.0 2.0/25 18.0 3.0/6 T 100.0 45.0 145.0 
30.0 3.0/10 30.0 2.0/15 T 75.0 60.0 135.0 
29.0 1.4/20 30.0 3.0/10 T 49.4 75.0 124.4 
36.0 3.0/12 30.0 2.0/15 L 90.0 60.0 150.0 
Wright. et 
al., 2006 
[68] 
37 
40.0 2.67/15 
Median 
19 (2-
125) 
20.0 4.0/5 SC 2 93.0 11.0 104.0 
8 
(range 1-
51) 
No cases 
30.0 3.0/10 20.0 4.0/5 CE 4 53.0 4.0 57.0 
30.0 3.0/10 20.0 4.0/5 SC 2 75.0 17.0 92.0 
50.4 1.8/28 20.0 4.0/5 CE 4 73.0 9.0 82.0 
37.7 2.51/15 20.0 4.0/5 SC 2 85.0 20.0 105.0 
T, thoracic; C, cervical; L, lumbar; SC, spinal cord; CE, cauda equina. BED is calculated using the formula: Eq.3. 
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T, thoracic; C, cervical; L, lumbar; S, sacral; SC, spinal cord; NR, not reported.  BED is calculated using the formula:  Eq.3.
 1st treatment  Re-irradiation  
Author Sample Total 
dose (Gy) 
Dose 
fx(Gy)/no fx 
Interval 
(months) 
Total dose 
(Gy) 
Dose 
fx(Gy)/no fx 
Nivel 
treated 
Value of 
α/β (Gy) 
Initial 
BED 
Irradiation 
BED 
Total 
BED 
Follow-up 
(months) 
Time to 
myelopathy 
(months) 
Nieder et 
al., 2006 
[31] 
7 
60.0 2.0/30 37 64.0 2.0/32 C-T 2 37.5 70.0 107.5 7 
No cases 
60.0 2.0/30 31 56.0 2.0/28 C 2 37.5 67.0 104.5 5 
70.0 
15 x 2 Gy 
followed by 
twice-daily 
radiotherapy 
with 1.8 Gy in 
the morning 
and 1.5 Gy in 
the afternoon 
23 50.0+12.0 2.0/25+3.0/4 C 2 80.0 43.0 123.0 10 
59.4 1.8/33 12 45.0 1.8/25 C 2 96.0 85.5 181.5 8 
36.0 3.0/12 30 30.0 2.0/15 L-S 4 63.0 39.0 102.0 20 
44.8 1.6/10+1.8/16 96 36.0 2.0/18 T 2 83.5 72.0 155.5 5 
40.0 2.5/16 26 30.0 2.0/15 L 4 65.0 45.0 110.0 17 
Maranzano 
et al., 2011 
[73] 
12 
8.0 8.0/1 31 8.0 8.0/1 
SC 2 
40 40.0 80.0 
SI No cases 
8.0 8.0/1 9 16.0 2.0/8 40 80.0 120.0 
8.0 8.0/1 9 8.0 8.0/1 40 40.0 80.0 
8.0 8.0/1 5 8.0 8.0/1 40 40.0 80.0 
8.0 8.0/1 2 8.0 8.0/1 40 40.0 80.0 
8.0 8.0/1 4 20.0 5.0/4 40 60.0 120.0 
Sahgal et 
al., 2012a 
[40] 
19 
37.5 2.5/15 5 24.0 8.0/3 C 
2 
 
84.4 120 204.4 4 
No cases 
39.1 2.3/17 39 25.0 5.0/5 L 84.1 87.5 171.6 7 
30.0 3.0/10 6 24.0 6.0/4 L 75 96 171 5 
50.0 2.0/25 11 24.0 8.0/3 T 100 120 220 8 
40.0 1.82/22 81 20.0 10.0/2 T 76.4 120 196.4 55 6 
25.2 0.9/28 70 21.0 10.5/2 T 36.5 131.3 167.8 29 5 
21.2 4.24/5 11 14.0 14.0/1 T 66.1 112 178.1 17 3 
51.9 1.85/28 18 33.0 11.0/3 C 99.9 214.5 314.4 11 8 
43.2 2.88/15 12 16.0 16.0/1 T 105.4 144 249.4 3 3 
Sahgal et 
al., 2012b 
[57] 
66 
   25.0 12.5/2 T   181.3  17 9 
   24.0 8.0/3 C-T   120  9 9 
   16.0 16.0/1 Clivus-C1   144  24 13 
 NR  25.0 25.0/1 C NR  337.5 NR 40 13 
   25.0 25.0/1 C   337.5  39 5 
   18.0 18.0/1 T   180  24 12 
   16.0 16.0/1 C   144  8 3 
   14.0 14.0/1 T   112  16 6 
   30.0+14.0 3.0/10+14.0/1 C   187  23 15 
Table 13 (cont.) Summary of published reports of treatments performed using re-irradiation. 
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4.2.2 Pathophisiology 
Radiation injury to the spinal cord is among the most studied experimental models of 
radiation injury and probably is the most fully documented clinical radiation complication. 
To the thoracic cord, it is still apparent that its sensitivity to radiation is substantially less 
than that of the cervical cord. A significant oxygen effect exists, and it is possible that the 
thoracic cord is intrinsically less well oxygenated. Extrinsic conditions, such as smoking 
history or effects of lung cancer may result in the patients with thoracic irradiation having 
less well oxygenated nervous tissues. Haemoglobin levels are significantly greater in 
thoracic patients with myelopathy that in those without myelopathy treated to the same 
dose [74]. 
The incidence of cervical myelopathy at 45Gy is, approximately, 0.03% and at 50Gy is, 
approximately 0.2%. Large lengths of cord, concomitant chemotherapy and other factors 
may increase this incidence [74]. 
Spinal cord, besides being one of the most dose-limiting organs in radiotherapy, is also 
a risk organ present in several neoplasms. It is a serial architectural organ, being very 
sensitive to radiation in small portions of its extension. There is a possibility that the 
sensitivity of the spinal cord depends on the organization and structural distribution of its 
functional subunits (FSU), since there are structural differences between the different 
spinal segments. These differences are mainly patented in grey and white matter [51, 
52].  
Histolopathology, changes of late lesions may include [46]: 
▪ Reactive gliosis; 
▪ Demyelination; 
▪ Necrosis confined to white matter; 
▪ Changes in both white and grey matter. 
In rat studies it was found that after delivery of single or fractionated doses in the spinal 
cord, rats developed paralysis of the lower limb 4 to 7 months after necrosis of the white 
matter. Necrosis and demyelination of the white matter occurs generally in the absence 
of gross vascular abnormalities. Functional deficits associated with vascular damage are 
variable, and they are observed much later and after lower doses in rodents and in 
human myelopathy [46]. 
Recently, animal studies have been conducted on the influence of small volumes and 
non-homogeneous irradiation with steep dose gradients along the cord to simulate 
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SBRT. The data obtained were conflicting. In the case of the rat, it was observed that 
when irradiating the spinal cord there was a significant volume effect after proton 
irradiation and that there was evidence of differential regional radiosensitivity in the spinal 
cord. On the other hand, in studies on pigs it was found that no significant volume 
dependence was observed. These cord irradiation studies described histopathological 
changes like the studies using homogeneous doses along the cord [46]. 
One of the characteristics of delayed spinal cord injury is demyelination. 
Oligodendrocytes are the cells responsible for myelination in the lesion response. After 
irradiation, oligodendrocytes and oligodendrocyte progenitor cells (OPCs) were 
observed to undergo apoptosis in the rodent spinal cord due to a p53-mediated 
response. The assay demonstrated an initial loss of the clonogenic OPC pool in rat spinal 
cord after irradiation. Followed by dose dependent recovery and a second decline 
between 4 and 5 months after paralytic doses. So far, there is no evidence of a causative 
association between acute oligodendroglial apoptosis after irradiation and late observed 
demyelination. 
The fundamental biologic mechanism of RM remains unclear. The actual model suggests 
that mitotic death of endothelial cells results in blood-spinal cord barrier (BSCB) 
disruption. This disruption leads to vasogenic edema, hypoxia and an inflammatory 
cascade resulting in demyelination and necrosis.  
The effects arising from the volume of irradiated bone marrow may be related to vascular 
supply, collateral circulation and/or the ability to re-establish damaged vasculature 
through revascularization. There is also the issue of the release of cytokines and 
mediators of inflammation. Their release may be affected by the irradiated volume 
because the larger the volume the greater the release of these potentially harmful 
substances [45]. 
In summary, recovery from initial damage is well established. The amount of recovery 
seems to be influenced by different factors, with initial damage expressed as a 
percentage of cord tolerance being the most important one. Time interval between the 
first treatment and re-treatment is also important as it is estimated as percentage 
recovery. 
The real total tolerance of the spinal cord may be about 130% of the tolerance dose for 
the first treatment as estimated by Kogel [32]. Although the general phenomenon of 
repair occurs in humans, caution is necessary when translating experimental animal data 
to the clinical setting because of the life span, latency and dose response difference [75]:  
61 
 
▪ Histological pattern of myelopathy in animals differs from those found in humans; 
▪ Repair kinetics is probably different, and the time to achieve maximal repair and 
re-tolerance in humans [76]. It is of extreme interest to consider the knowledge 
about the kinetics of the evolution of the hidden damages caused by the previous 
treatment. 
In general, a higher re-treatment dose can be given following lower initial doses and 
longer intervals between treatments. From the sparse clinical and primate data, it 
appears that at least 50% recovery from 45Gy would be obtained 2 years after treatment.  
 
4.2.3 Dose selection 
Initially, radiation oncologists using SBRT used ablative hypofractionation, i.e., few 
fractions with a dose greater than 8Gy per fraction, to create a more drastic impact on 
cancer treatment [66]. 
Several studies were carried out, where the only variable was the radiation dose. In these 
studies, 25 to 100 patients were registered, which allowed an assessment of toxicity and 
early efficacy. This phase of treatment allowed the discovery of the most effective dose, 
which defines the limits of treatment in a shorter period, since patients were exposed to 
very low or very high doses [66]. 
The choice of patients is a very important step, especially when it comes to a re-
treatment. Decisions must consider the current situation of the patient: the degree of 
systemic disease, the time between the first and second irradiation, the time of local 
relapse, and if there was surgery (Table 14) [77]. 
The strengths of SBRT treatment include high rates of tumor eradication through 
convenient and non-invasive outpatient treatment. On the other hand, the most observed 
disadvantages are the possibility of causing toxicity, such as ulceration, stenosis, fibrosis 
and even necrosis, which can occur considerably later after treatment [66]. 
Patients undergoing SBRT treatment should have a stable spine that is assessed 
through the Spinal Instability Neoplastic Score (SINS). SINS stratify the risk of lesions 
by location, pain, type of injury, alignment of the spine and the presence of collapse of 
the vertebral body and posterolateral involvement of spinal levels [60]. 
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Table 14 The inclusion and exclusion criteria for SBRT. Adapted from: [47, 60, 63]. 
General criteria  
Inclusion Exclusion 
Good performance status Moderate and poor performance status 
Oligometastatic disease in ≤5 sites extracranial 
metastases 
Oligoprogression in patients with metastatic and/or 
rapidly progressive disease with limited life expectancy 
Oligoprogression in patients with oligometastatic disease 
Bone compression of neural structures; can cause spinal 
instability or neurological deficit 
Without or with minimal spine instability With spine instability 
Without or minimal epidural disease, i.e., Bilsky 0-1 
With moderate or high grade of epiural disease, i.e., 
Blisky 2 or 3 
Tumor is involved no more than 3 spinal levels 
(contiguous or non-contiguous) 
More than 3 spinal levels involved and/or presence of 
diffuse spinal disease 
Histology of the tumor called “radioresistant” Histology of the tumor called “radiosensitive” 
Failure to treat conventional radiotherapy previously 
performed 
Delivery EBRT within less than 5 months before 
performing SBRT treatment 
First treatment of SBRT delivered within 5 months or 
more before a second treatment of SBRT 
First treatment of SBRT delivered within 3 months or 
less before a second treatment of SBRT 
Detection of spinal metastases through CT and MRI 
Incapability to support a near-rigid or supine 
immobilization due mechanical spine instability 
High risk of recurrence or gross residual disease Systemic disease out of control 
Gross tumor more than 2 mm from spinal cord without 
signal for initial surgery 
Presence of significant or progressive neurological 
deficit 
Impossibility of surgery due to the existence of two or 
more diseases simultaneously in the same patient or 
due to the refusal of the patient 
With connective tissue disease. 
Histological confirmation of neoplastic cells in the patient Limited survival 
 
The best survival rate has been verified with female patients, with better status 
performance, based on previous surgery at the SBRT site, presence of solitary spinal 
metastasis, and a long disease-free interval [60]. 
A multi-institutional study demonstrated how re-treatment using SBRT is safe and 
effective. The initial treatment, performed with conventional radiotherapy, was prescribed 
with doses of 3Gy per fraction, completing a total of 10 fractions. In the re-treatment, 
mean doses of SBRT were 16.6Gy in 1 fraction or 24Gy in 3 fractions. After 6 and 12 
months of re-treatment, local control was 93% and 83%, respectively. The reported 
toxicity was vertebral compression fracture (VCF), with a rate of 4.5%, and there were 
no reports of cases of myelopathy due to radiation [60]. 
According to Huo et al. [60], re-treatment using single fraction SBRT was able to predict 
better local control since it showed local control rates in a period of more than one year 
between 66% and 93%. On the other hand, studies using lower prescription doses, i.e., 
20Gy in 2 fractions and 20Gy in 5 fractions, showed lower rates of local control. 
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Fractionation differentiates the intrinsic radiosensitivity between the tumor and the spinal 
cord, allowing high doses of radiation to be safely delivered to lesions within the epidural 
space, where up to half of all recurrences occur after conventional radiotherapy. 
 
4.2.4 Vascular damage in tumors 
Initially, clinical trials were performed in the liver and lung for the treatment of primary 
and metastatic liver and lung tumors. These organs have parallel hierarchy, which leads 
to a lower tissue toxicity when irradiated. 
SBRT was tested in patients whose lung tumors were inoperable and had relatively small 
targets, making dosimetry more reasonable in the normal lung. As results, the control 
rate in primary tumors with SBRT was found to be within the range of 80%. However, 
the toxicity rates were quite low, with values between 15% -20%, even in the most fragile 
patients [66]. 
In a 1g tumor, it is known that there are up to 108-109 cells, suggesting that 8 to 9 log 
tumor cells should be eradicated to control tumors with this mass. The calculation by 
Brown et al., using conventional radiobiological principles, indicated that the radiation 
doses used in SBRT are insufficient to kill all clonogenic cells in tumors with a diameter 
of 1-3cm, if 10-20% of tumor cells hypoxic. On the other hand, SBRT was effective in the 
treatment of tumors with diameters greater than 5-6 cm when irradiated with 30-60 Gy in 
2 to 5 fractions. Thus, SBRT, in addition to causing direct cell death, also causes indirect 
cell death through vascular damage, which occurs when the tumor is exposed to high-
dose hypofractionated radiation [62].  
New tumor vessels form due to the increasing need for nutrients, including oxygen in 
growing tumors. These blood vessels are composed of a single layer of endothelial cells, 
incomplete and disorganized basement membranes. Tumor endothelial cells, which are 
irregularly shaped, are linked to others with large gaps between them, which are 
obstructed by tumor cells [62]. 
Abnormal blood vessels in the tumor have gaps between endothelial cells or incomplete 
basement membrane support. Although there is little information on the effects of high 
dose hypofractionation on human tumor vasculatures, there are many reports on the 
effects of high dose hypofraction on the vasculature of experimental tumors. 
Park et al., reported that endothelial cells retired from human breast cancer were more 
radiosensitive when compared to endothelial cells from adjacent normal breast tissues. 
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Although human functional vasculature remains unchanged or better during the initial 
period of conventional fractional radiotherapy, it gradually declines during the latter part 
of the treatment. Irradiation at doses greater than 10Gy in a single fraction or 20-60Gy 
in a limited number of fractions causes severe vascular damage leading to indirect death 
of tumor cells due to the acute decrease in blood perfusion, making the tumor 
environment hypoxic and without nutrients [58, 62]. 
 
4.2.5 Tumor hypoxia and SBRT 
Tumor hypoxia occurs in most human solid tumors (Figure 17). This feature contributes 
to the failure of many anticancer therapies such as surgery, chemotherapy and 
radiotherapy [78]. Hypoxia occurs due to uncontrolled proliferation of cancer cells once 
the tumor exhausts the nutrient and oxygen concentration from the normal vasculature 
and becomes hypoxic. 
 
 
 
 
Figure 17 Hypoxic tumor. Near the blood vessel the tumor has a lot of oxygen but the greater the distance 
the cells to the blood vessel the lower the oxygen concentration. 
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Recent modelling by Carlson et al., suggested that assuming daily fractionation and full 
reoxygenation between fractions, tumor hypoxia is actually more serious problem with 
SBRT (Figure 18) [78]. 
 
 
 
 
 
 
 
Figure 18 Tumor hypoxia can occur through two different mechanisms proposed by Thomlinson and Gray 
and Brown. Adapted from [78]. 
The following graph, adapted by Carlson et al., shows that the survival of tumor cells can 
increase up to 100 times when we apply a smaller number of fractions and a higher dose 
per fraction, which is observed by the letter A. This can represent a situation equivalent 
to a SBRT treatment.  In letter B, an increase in hypoxic fraction from 10% to 30% reflects 
nearly 10 times further resistance of tumor cells at this high dose hypofractionated 
regimen in this modelling study [78]. 
 
 
 
 
 
 
 
 
 
 
Figure 19 Survival curve of tumor cells as a function of dose per fraction supplied. It is assumed that daily 
fractionation and complete reoxygenation occurred between fractions. Adapted from [78]. 
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Description of the letters shown in figure 19 [78]: 
▪ A: For tumors with 10% hypoxia (fhyp = 0.1; red line) there is more than 2 log (100-
fold) of cell survival advantage (pointed with the orange arrow) if reduce the 
number of fractionations (as we shift right to left); 
▪ B: As hypoxic fraction increases from 10% (fhyp = 0.1; red line) to 30% (fhyp = 0.3; 
green line), there is additional 1 log (10-fold) of cell survival increase (pointed 
with the black arrow) at 5 fractionation treatments, at which the cell survival is 
already being much higher than that by hyperfractionation. 
One problem of SBRT is that there is no standard interval between each hypofraction: 
Several studies were performed with different fractionation intervals and all presented 
good clinical results. Some of the plans described by different authors were: Timmerman 
et al. [66], prescribed 18Gy per fraction × 3 fractions within 2 weeks, while Nagata et al. 
prescribed 12Gy per fraction × 4 over 5–13 days. In one study 50Gy was delivered over 
4 consecutive days, meaning 12.5Gy every day for 4 days [79]. 
To determine changes in tumor hypoxia before and after a single fraction of 20Gy, Hong 
et al. [78], used various techniques such as F-MISO PET imaging, pimonidazole and 
bioluminescence imaging in a mouse tumor model. It was possible to conclude that tumor 
hypoxia did not change significantly after irradiation. However, it was found that after 
high dose irradiation, the cells had a transient vascular collapse.  
Radiosensitizers are combined with the radiation to render tumor cells more sensitive 
when irradiated (Table 15). 
Table 15 Example, nimorazole has better results at high doses (doses being equivalent to dose used in 
SBRT) [78]. 
 
 
 
Wittenborn and Horsman have demonstrated that the dose of radiation to control 50% of 
tumors (TCD50) can be reduced from 29.7Gy to 2.5Gy when 3x15Gy was combined with 
nimorazole 30 minutes prior to each fraction [78]. 
 
Combination of treatment Value of TCD50 (Gy) 
Radiation: 3 fractions x 15Gy 29.7 
Radiation + 1 x nimorazole 20.1 
Radiation + 3 x nimorazole 2.5 
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4.2.6 Rs impact 
The classical fractionation principles, i.e., the Rs of radiobiology, explain the effects of 
high doses of ionizing radiation on tumors and adjacent normal tissues. Like conventional 
fractional radiotherapy, it is of interest to refer to how these biological mechanisms apply 
in this new method of radiotherapy (Table 16). 
Some radiobiological questions remain without response regarding the evaluation of the 
doses administered in the SBRT and the effect of high doses per fraction. While in 
conventional radiotherapy the treatment time is approximately 5 minutes, in the SBRT 
the treatment session takes about 15-40 minutes  
Table 16 Impact of radiobiological mechanisms in SBRT treatment. 
Biological mechanisms Description 
Repair of sublethal 
damage 
Treatment with SBRT has a longer irradiation time when compared to conventional 
radiotherapy. With this treatment, repair of sub-lethal damage may occur during 
prolonged exposure to radiation. After 30 minutes, the sublethal damage repair is greater 
than >10% [62, 80]. 
Repopulation of cells after 
radiation 
Repopulation occurs depending on the type of tissue and the dose of radiation 
administered. In conventional radiotherapy, tumor cell repopulation occurs within 2 to 3 
weeks after start of RT. Thus, it is possible that the repopulation of tumor cells may occur 
earlier in the treatment of SBRT or SRS than in conventional RT [62]. Delivering a higher 
dose should mitigate any clonal expansion and thus offer a significant advantage to 
rapidly dividing tumors [76]. As treatment time of SBRT lasts is short, 2 weeks at most, 
repopulation of tumor cells will not be a problem [80]. 
Redistribution of cells 
within the cell cycle 
Reducing the number of fractions alters the probability of irradiating a cohort of cells as 
they move into a radiosensitive phase [81]. 
After irradiation with a single fraction of 15–20Gy, cells are indefinitely arrested in the 
phases of cell cycle where they were irradiated and undergo interphase death. After 
irradiating the cell cycle with a dose of 20Gy in a single exposure, cell cycle progression 
was delayed, and many cells underwent necrosis in the phases of the cycle where they 
were irradiated. The cells that were irradiated slowly progressed to the G2 phase and 
died [62]. 
Reoxygenation of the 
surviving cells 
In SBRT, due to the vascular damage caused by the high doses of radiation, the 
intratumoral environment becomes hypoxic. Hypoxic cells reoxygenated when irradiated 
with a relatively low dose per fraction, i.e., less than 10Gy [80]. Following administration 
of a SBRT or SRS treatment, massive vascular destruction of the tumor occurs, and 
reoxygenation of hypoxic cells occurs 2-3 days after irradiation. As oxygen consumption 
declined dramatically after massive death of tumor cells, surviving hypoxic cells can be 
reoxygenated. Changes in the oxygenation status of the tumors after irradiation with 
high doses are still unclear [62]. SBRT has a theoretical disadvantage because of the 
short delivery time. Although this might be compensated by the high doses per fraction. 
Radiosensitivity 
SBRT attenuates differences in tumor death that are directly attributable to variations in 
radiation sensitivity of individual tumor cells. Large doses per fraction and short 
treatment time used in SBRT provides less opportunity for the development of resistant 
stem cells [81]. 
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Regarding radiobiology, it is of interest to mention how these biological mechanisms 
apply in this method of radiotherapy. The major question raised is whether the dose of 
radiation administered in intervals is equivalent to that administered without breaks, since 
repair of sublethal damage occurs within the time interval between the administration of 
two doses of radiation [62, 79]. According to Kim et al. [62], it is indicated that 
radiobiological factors are not relevant to the single dose in SBRT or SRS. 
Tumor hypoxia may actually be a more serious problem with SBRT due to a reduction in 
reoxygenation between fractions as associated with small number of SBRT fractions (1 
to 5) in comparison with conventional RT. This problem could be overcome if the next 
fraction of SBRT could be to deliver after tumor reoxygenation. And although there are 
no standard intervals between the high doses of SBRT, good clinical results were 
obtained despite different fractionation intervals [78]. 
As SBRT uses doses per fraction much higher than conventional radiotherapy, the 
radiobiological mechanisms underlying radiation response have been subject to 
controversy, regarding their application to extreme hypofractionation [79]. 
Hypofractionation does not follow the basic principles of radiobiology to explain tumor 
responses obtained by conventional fractionation schemes.  
Thus, the relevance of the Rs of radiobiology in a scenario of hypofractionation is 
controversial:  As the treatment time decreases, repopulation will be of lesser importance 
and the clinical significance of cell redistribution in the cell cycle, in a scenario of 
hypofractionation, is unclear. The advantages and disadvantages of the radiobiological 
mechanisms are presented in (Table 17). 
In spite of the controversy around the relevance of the 5Rs in SBRT, [62, 82], it is now 
clear that these radiobiological concepts are sufficient to explain the impressive results 
obtained from clinical studies are the result of much larger biologically effective doses 
delivered [83]. 
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Table 17 Advantages and disadvantages of radiobiological mechanisms. Adapted from [81]. 
Radiobiological 
mechanisms 
Advantage Disadvantage 
Repair 
Improvements in the technique of dose delivery 
allows dose reduction delivered to adjacent 
normal tissues. 
Limitation of the number of cycles of damage 
and repair that separate the tumor response 
from normal tissue toxicity. 
Repopulation 
Tumor repopulation is greatly reduced or 
eliminated during a treatment with less 
fractions. It is specifically relevant for radiation-
resistant tumor stem cells. 
None 
Redistribution 
The distribution of the cells will be affected by the reduced number of fractions. The clinical 
significance is still unknown, so it is not possible to enumerate the advantages and disadvantages 
of this biological mechanism. 
Reoxygenation None 
A smaller number of fractions potentially 
reduces reoxygenation between fractions, 
which results in an increase in radioresistance. 
Radiosensitivity 
A single fraction dose greater than 10Gy may 
trigger apoptosis of endothelial cells. 
Normal late-reacting tissues are more 
radiosensitive at higher doses per fraction and 
so the risk of late complications is higher at 
higher doses per fraction. 
 
4.2.7 Linear-Quadratic Model  
The linear-quadratic (LQ) model is advantageous for the calculation of iso-effect doses 
in the treatment of cancer with conventional multi fractionated radiotherapy. This model 
assumes that two-strand DNA breakdown is responsible for radiation-induced 
clonogenic cell death and that hypoxic cells are fully reoxygenated during the fractional 
irradiation interval [62]. 
Due to the quadratic component in the formula, many authors have suggested that the 
LQ model is used to overestimate cell death with increasing radiation dose. Interestingly, 
despite the problem inherent in the LQ model, some researchers have reported that the 
LQ model fits certain clinical results of SBRT and stated that direct cell death due to DNA 
damage is enough to explain the high clinical efficacy of SBRT. The tumor cell survival 
curve in vivo curves downward as the radiation dose increases above approximately 
10Gy, which occurs due to secondary cell death caused by vascular damage [58, 62]. 
70 
 
Thus, it is permissible that, in a given clinical situation, cell death calculated by the LQ 
formula incidentally does not exceed estimates, but approximates total SBRT cell death, 
which encompasses not only direct and indirect cell death [62]. 
 
4.2.8 Limitations and constraints of SBRT 
The dose limitations for the spinal cord in an SBRT treatment are [46]: 
▪ Limiting the spinal cord point maximum volume to a safe dose, based on a 
conventional fractionation, of 8 to 10Gy; 
▪ Limiting the safe dose to a larger volume and / or volume of the irradiated cord, 
thus the maximum dose within the cord is higher than that which was thought to 
be tolerable; 
▪ Limit the safe dose of the spinal cord to the thecal sac or to the conjugation of 
the spinal cord with a margin of uncertainty of 1.5 mm beyond the cord and not 
the "true" cord itself to reduce the technical uncertainties in dose delivery. 
 
Brenner et al. (2008) [33] described the use of the LQ model applied to doses within the 
range of extreme hypofractionation.  
In vitro and in vivo experiments demonstrated that: 
▪ In vitro experiment: Garcia et al., conducted a research where they used a colony 
test to measure cell survival. The surviving cell fractions were recorded in the 0-
16Gy dose region. To estimate the dose regions where the single-fraction LQ 
model adjusted the data, the authors of this study adjusted the data from 0-4Gy 
and then 0Gy to progressively higher doses, verifying if the model fit the bottom 
of the dose increase. In summary, it was verified that the LQ model does not 
decrease its fit quality until doses above 15Gy [33]. 
▪ In vivo experiment: There were several quantitative parameters in vivo that allow 
to verify the agreement of the LQ model in the 2-20Gy range. The shape of the 
graph, presented in figure 20, called “the reciprocal dose Fe graph”, is such that 
if the LQ model applies the inserted data would form a straight line. The portion 
of the reciprocal dose provides a visual indication of how in vivo data matches 
the LQ model in the dose range of interest. The quantitative parameters depicted 
in the following image are consistent with the LQ model, over a wide range of 
doses per fraction, including doses of interest in hypofractionation [33]. 
71 
 
 
 
 
 
 
 
 
 
 
Brenner et al., [33] concluded that the LQ model is mechanically plausible for designing 
protocols in the dose range by fraction of 2-10Gy, above 10Gy and the model is expected 
to become progressively less accurate. However, animal studies have shown that the 
model is acceptable in clinical trials with 15-18Gy fractions. There are more sophisticated 
methods for assessing agreement with the LQ model, due to the uncertainties inherent 
in the data. However, with the studies analysed, the LQ model applies to fractions of 
20Gy, approximately.  
As radiosurgery is increasingly being employed in the treatment of spinal lesions, and 
although reports of toxicity are rare, the follow-up time is short and patient numbers 
small. The effect of concurrent chemotherapy is essentially unknown in that situation. 
Also, the uncertainty in dose calculation results in BED uncertainty and the difference 
between the prescribed dose and the dose given are limiting factors of the data published 
so far [31]. 
Most studies related to re-irradiation are based on data from retrospective studies or 
small prospective studies. In addition to this, re-irradiated populations are more 
heterogeneous than patients with local or regional recurrence or second tumors [6]. 
The major paradigm associated with spinal cord re-irradiation is related to the lack of 
evidence regarding repair of long-term damage in this organ. There is a greater 
uncertainty related to tolerance rates during re-irradiation, since most of the existing data 
are derived from results obtained with animals, revealing long-term damage recovery [5]. 
Figure 20 Iso-effect data for late response from 3 different regions, represented by □○▲, of the rat spinal 
cord. Where ◊ represents acute skin reactions in mice, ● for early and      late murine intestinal damage. The 
data are plotted in a “reciprocal-dose Fe” form26 such that, if they follow an LQ relationship, the points fall 
on a straight line. Adapted from [33]. 
72 
 
As SBRT is increasingly being employed in the treatment of spinal lesions, and although 
reports of toxicity are rare, the follow-up time is short and patient numbers are still small. 
The effect of concurrent chemotherapy is essentially unknown and needs to be 
investigated.  
The consensus is that SBRT is appropriate in the postoperative cases in patients with 
limited disease, radioresistant tumors and as another treatment strategy after failure of 
conventional radiotherapy treatment. 
The optimal dose prescription for SBRT remains controversial. On the one hand, a single 
fraction treatment results in better local control rates than obtained with conventional RT. 
This may be the result of larger biologically effective doses delivered with SBRT. 
Alternatively, higher rates of local control following single fraction treatment in 
retrospective series may simply reflect better outcomes in patients with less aggressive 
disease [84]. 
 
4.2.9 Consensus guidelines 
15 radiation oncologists and 5 neurosurgeons, representing 19 centers in 4 countries 
and having experience in 1300 cases of spine SBRT, have presented a handbook 
on safe practice guidelines on SBRT treatment.  
The consensus indications and contraindications for postoperative spine SBRT are 
(Table 18): 
Table 18 Consensus indications and contraindications. Adapted from [84]. 
 
Concerning the delineation of the target volume, most experts agreed on the regions 
to be included in the design of the structures. For target volume delineation, in 
preoperative cases MRI is performed and in postoperative cases T1-weighted MRI 
(obtained with and/or without gadolinium) to the CT simulation is obtained. For spinal 
cord delineation/thecal sac and paraspinal disease extension, T2-weighted MRI or 
For postoperative spine SBRT 
Indications 
Have 1-2 primary radioresistant levels of adjacent disease; 
Previously performed radiotherapy. 
Contraindications 
Have more than three contiguous vertebral bodies; 
Features complete spinal cord injury without preservation of motor or 
sensory function, i.e., ASIA Grade A status. 
Features spinal cord compression without any cerebrospinal fluid (CSF) 
around the spinal cord, i.e., postoperative Blisky Grade 3 residual. 
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CT myelogram in cases of significant hardware artefacts are similarly recorded [60, 
84]. 
Table 19 summarizes the structures that should be included in each type of volume 
or structure for a correct treatment planning. 
Table 19 Consensus and predominant practices for the delineation tumor volume for postoperative spine 
SBRT. Adapted from [84]. 
Volume Include 
Planning target volume (PTV) 0-2mm expansion from CTV 
Clinical tumor volume (CTV) 
Entire extent of preoperative tumor, anatomic compartment involved, & any 
postoperative residual; 
Surgical instrumentation & incision not included (unless involved); 
Prophylactic circumferential treatment of epidural space controversial; 
Additional expansion up to 5 mm for paraspinal extension controversial; 
Consider an additional expansion of up to 5 mm cranio-caudally beyond known 
epidural disease extent based on pre- and postoperative imaging 
Gross tumor volume (GTV) Based on MRI – postoperative residual 
Spinal cord 
True spinal cord: postoperative T2-weighted MRI or CT myelogram (in cases 
of significant hardware artefact) 
Spinal cord risk volume (PRV) 0-2mm expansion of spinal cord volume 
 
Prescription doses and times of fractionation were controversial among radiation 
oncologists. For re-irradiation, with a previous irradiation treatment, the repair and the 
time interval between the previous RT and the spinal SBRT were included in the 
calculation of the cord constraints. The following table represents the common dose and 
fractionation schemes for various possible clinical situations (Table 20). 
Table 20 Clinical scenario versus reasonable dose and fractions. Adapted from [84]. 
Clinical scenario  Reasonable dose x fractions 
No prior RT; 
Single vertebral level; 
No epidural disease 
16-24Gy x 1 fraction; 
12Gy x 2 fractions; 
8-10Gy x 3 fractions. 
No prior RT; 
Multiple vertebral levels and/or epidural disease 
16-18Gy x 1 fraction; 
1Gy x 2 fractions; 
8-10Gy x 3 fractions; 
6-8Gy x 5 fractions. 
No prior RT; 
Epidural disease 
16-18Gy x 1 fraction; 
12Gy x 2 fractions; 
8Gy x 4 fractions; 
6-7Gy x 5 fractions. 
Prior RT; 
Any extent of epidural disease 
16-18Gy x 1 fraction; 
12Gy x 2 fractions; 
7-10Gy x 3 fractions; 
8-10Gy x 4 fractions; 
5-7Gy x 5 fractions. 
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The treatment plan approved by the Radiation Therapy Oncology Group (RTOG) for 
the calculation of dose within a medium with heterogeneities should be used in all 
cases of SBRT in the postoperative column. The treatment planning system and the 
corresponding algorithm are shown in (Table 21). 
Table 21 Treatment planning algorithms for calculation of dose approved by RTOG. Adapted from [84]. 
Treatment planning system Algorithm 
BrainLab Monte Carlo 
Corvus Monte Carlo 
CyberKnife Multipan Monte Carlo 
Eclipse AAA (analytical anisotropic algorithm) 
Eclipse Acuros 
Helax Collapsed cone 
In house Monte Carlo 
Monaco Monte Carlo 
Pinnacle Collapsed cone convolution-adaptive convolve 
Tomotherapy Convolution superposition 
XiO Superposition-fast superposition 
 
The time between initial treatment and re-treatment in determining spinal cord 
restrictions is controversial. On the dosimetric target, most radio-oncologists indicated a 
preference that had as goal 95% to 100% of the prescribed dose to cover 95% of the 
PTV. 
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Chapter 5 
 
5. Conclusion and Future work  
In this final chapter the main conclusions are presented after the elaboration of this work. 
An analysis of the accomplishment of the initially stipulated goals will be presented. 
Finally, a reference for possible future work to develop in this area of radiotherapy. 
 
5.1 Final conclusions  
Re-irradiation is a very important tool due to the increasing survival of cancer patients 
and the development of second tumors and recurrences. To evaluate the necessary 
conditions for re-irradiation it is necessary to consider several facts associated with the 
first treatment. Factors like the total dose or dose per fraction, the volume and the 
segment of the spinal cord to be irradiated and the time interval between irradiations are 
very important. Re-irradiation must be delivered only when the BED of the first treatment 
is lower than 102 Gy2, when the time interval between irradiations is higher than 6 
months, and total BED is lower than 135Gy2. 
From the results shown in the literature, we can conclude that the SBRT treatment is 
highly effective as it can deliver ablative doses to the target while sparing critical organs 
at risk. Although the studies analysed encourage us to practice this type of treatment, it 
is necessary to mention that the lack of follow-up of the patients in several studies is a 
worrying point. 
The table developed by Nieder et al., [31] is an interesting working basis for the radiation 
oncologists to use on a re-treatment and thus to consider the risk of the patient 
developing radiation myelopathy. 
Similarly, the article published by Redmond et al., [84] is a guide for the practice of SBRT 
because it concludes information regarding with patients are eligible for this type RT 
treatment.  
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5.2 Objectives achieved 
The main objective of this work was to conduct an analysis of available articles dealing 
with the subject of "dose effects on spinal cord re-irradiation". 
From this analysis a series of conclusions are put forward regarding dose, fractionation, 
tolerance tissues, regarding re-irradiation of spinal cord.  
A review article was been submitted to AAPM Journal, Medical Physics. This article can 
be consulted Annex B in the section "Appendix B". 
 
5.3 Future work  
From work presented in this thesis it is clear that some issues still require further 
elucidation: 
▪ Understanding the importance of the spatial distribution of dose (and, hence, the 
utility of partial circumferential sparing); 
▪ More data is necessary to better estimate the risk of acute and long-term toxicity 
(including all information regarding history of concurrent and prior therapies, time 
interval from 1st treatment, dose and fractionation, and treatment-related toxicity, 
particularly neurologic deficits, for SBRT of spinal lesions); 
▪ Furthermore, when adverse events do occur, it would be most helpful if the 
involved critical structure doses would be referred; 
▪ Further investigation of radiosensitinzing drugs that act in synergy with the high 
doses of SBRT. 
  
77 
 
 
 
Appendix A 
Annex A – Framework and development of the BED formula 
The linear quadratic model of cell survival is used to describe the relationship between 
the total iso-effective dose and the dose per fraction in fractionated radiotherapy. This 
model can create an equilibrium environment between the acute and late reactions and 
the effects on the tumor, depending on the dose change per fraction and the total dose 
[9]. 
Cell death by irradiation can be expressed by [29]: 
𝐶𝑒𝑙𝑙 𝑑𝑒𝑎𝑡ℎ = 𝐸 = 𝑛(𝛼𝑑 + 𝛽𝑑2) (𝐸𝑞. 5) 
Where: 
▪ 𝛼 and 𝛽 represent the radiosensitivity coefficients; 
▪ 𝑛 represents the number of fractions; 
▪ 𝑑 represents the dose per fraction. 
Thus, the total dose (𝐷) is defined as (Eq.6): 
𝐷 = 𝑛𝑑 (𝐸𝑞. 6) 
Considering the progressive reduction of d until it approaches zero, and although the 
number of fractions must then increase to maintain the same effect, 𝛽𝑑2 will be very 
small when compared to 𝛼𝑑. Thus, when 𝑑 has a very small value, the equation is 
approximated as (Eq.7) [29]: 
𝐸 = 𝑛 𝛼𝑑 = 𝛼𝐷 (𝐸𝑞. 7) 
Equation 7 shows that the total dose (D) at a very low dose per fraction represents the 
highest total dose required to obtain a specific effect. The total dose required is the 
definition of BED for situations where cell repopulation can be ignored (Eq. 8) [29]: 
𝐵𝐸𝐷 = 𝐷 =
𝐸
𝛼
 (𝐸𝑞. 8) 
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The formula that considers the incomplete repair of damages is represented in (Eq. 9), 
where Hm is a tabulated value and represents the amount of unrepaired damage, being 
m the number of fractions [9]: 
𝐸𝑄𝐷2 = 𝐷 
𝑑(1 + 𝐻𝑚) + (
𝛼
𝛽⁄  )
2 + (𝛼 𝛽⁄  )
 (𝐸𝑞. 9) 
The next formula (Eq. 10) considers repopulation that occurs in tumors and acute 
response tissues, where TP and TK are tabulated values [9]: 
𝐵𝐸𝐷 = 𝑛𝑑 [1 +
𝑑
(𝛼 𝛽⁄  )
] −
0,693
𝛼𝑇𝑃
(𝑇 − 𝑇𝐾) (𝐸𝑞. 10) 
 
Where: 
▪ T: Total number of days; 
▪ TP: Cell doubling time in a tissue during radiotherapy; 
▪ TK: Kick-off time: the apparent starting time of rapid compensatory repopulation 
in tumor or tissue after the start of treatment. 
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Appendix B 
Annex B – Submission of a review article to Medical Physics AAPM 
In October 2018, I submitted a review article in the journal "The International Journal of 
Medical Physics Research and Practice" belonging to the American Association of 
Physicists in Medicine (AAPM). Figure 21 is a proof. 
Figure 21 Review article submitted to "The International Journal of Medical Physics Research and Practice". 
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A copy of the article: 
Radiobiology of spinal cord re-irradiation: effect of time, 
dose and fractionation 
Abstract: Advances in biology and physics have allowed increased precision and accuracy in 
radiotherapy in order to maximize tumor damage and to minimize lesions in the dose limiting 
adjacent normal tissues. The spinal cord is the most critical organ at risk. Radiation myelopathy 
is one of the most devastating complications of clinical radiotherapy resulting in severe and 
irreversible morbidity. Assessment of the impact of dose and fractionation schemes on tissue 
tolerance has been a major area of research in radiation oncology. As a result of greater accuracy 
and effectiveness of cancer treatment, patient survival rates increase, and radiation oncologists 
are frequently faced with the problem of treatment of local recurrence or second tumors located 
within or close to previously treated sites. Initial dose influences different time intervals from 
tissue tolerance to re-irradiation as well as conditioning the recovery of radiation damage in the 
first treatment. It is possible to administer a higher dose in the re-irradiation if smaller doses were 
used at the first treatment and if the intervals between treatments were longer. Radiation 
myelopathy is a rare late toxicity effect in the modern era of 3-dimensional conformal 
conventionally fractionated RT. This devastating late effect has re-emerged as a direct result of 
SBRT practice, where high-dose radiation is delivered adjacent to the spinal cord to be spared. A 
comprehensive search was performed including relevant articles referring to “spinal cord”, “re-
irradiation” and “myelopathy”.  The biologically effective dose (BED) was calculated and the 
results are discussed considering radiobiological mechanisms. 
Keywords: Spinal cord, Radiobiology, Re-irradiation, Tolerance. 
Introduction  
Advances in biology and physics have allowed increased precision and accuracy in radiotherapy 
in order to maximize tumor damage and to minimize lesions in the dose limiting adjacent normal 
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tissues. This led to an evolution in the treatment of tumors and consequently survival rates have 
been increasing for a wide variety of malignancies. 
The dose of radiation that can be delivered for tumor control is limited by late and generally 
irreversible injury of the surrounding normal tissues and organs at risk (OAR), also known as late 
effects. 
The spinal cord is the most critical organ at risk. It is typically located near the vertebral tumor 
target volume and has been classically described as an organ with a serial functional architecture 
and as such damage to small volumes within the structure can have a major impact on neurologic 
function (1).  
Spinal cord thus limits the dose to tumors in the head and neck, thoracic and upper abdominal 
regions as well as in cases of bone metastasis in the spine (this is estimated to occur in about 40% 
of cancer patients) (2). 
As a result of greater accuracy and effectiveness of cancer treatment, patient survival rates 
increase, and radiation oncologists are frequently faced with the problem of treatment of local 
recurrence or second tumors located within or close to previously treated sites (3).  
Spinal cord doses and tolerance 
Radiation myelopathy is one of the most devastating complications of clinical radiotherapy 
resulting in severe and irreversible morbidity. Assessment of the impact of dose and fractionation 
schemes on tissue tolerance has been a major area of research in radiation oncology. 
A comprehensive set of dose tolerance limits for normal tissue to radiation therapy (RT) became 
a reference landmark in radiation oncology (4). In an extensive review of spinal cord re-irradiation 
it was concluded that a dose of 50Gy in the spinal cord causes a risk of myelopathy of 0.2%. If 
the dose increases to 59Gy the risk of myelopathy increases to 5% (5, 6).  
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There is consensus regarding the dose of tolerance accepted in the spinal cord that with 
conventional fractionation of 2Gy per day including the full cord cross-section, a total dose of 
50Gy, 60Gy and 69Gy is associated with a 0.2, 6 and 50% rate of myelopathy (7).  
As a result, standard RT involving spinal cord treatment delivers a maximum dose of 50Gy with 
conventional fractionation 1.8-2Gy per fraction. Data obtained experimentally indicates that dose 
reduction per fraction below 2Gy does not significantly alter the absolute dose-response (5). 
Dose and fractionation  
The biological effects of a physical dose depend on the radiobiological features of the tissue, total 
dose and fractionation scheme, as well as total treatment time.  
The biologically effective dose (BED) is the parameter which quantifies the overall biological 
effect on a given tissue. The equation for BED provides a simple and straightforward way to 
compare doses from different fractionation schemes, which in turn have different biological 
effects (8, 9, 10). 
The biologically effective dose indicates the radiosensitivity of normal or tumor cells to the effect 
of radiation. Using  BED, it is possible to overcome the difficulty in clinical practice of calculating 
the total dose when a change in dose per fraction occurs: 𝐵𝐸𝐷 = 𝑛 × 𝑑 × [1 + 𝑑 (𝛼 𝛽⁄ )], where 
n represents the number of fractions and d represents the dose per fraction, with  𝛼 𝛽⁄  representing 
the sensitivity of the tissue. 
For acute response tissues the 𝛼 𝛽⁄  ratio is within a range of 7-20Gy, whereas for late response 
tissues the 𝛼 𝛽⁄  ratio generally ranges from 0.5-6Gy. The increase in BED values is higher in 
tissues with low 𝛼 𝛽⁄  ratios, i.e., it is higher in late response tissues than in acute response tissues 
(9,11). 
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The 𝛼 𝛽⁄  values for cervical and thoracic cord are 2Gy or 4Gy, respectively. In this way, a dose 
of 50Gy given in 2Gy daily fractions is equivalent to a BED of 100Gy2 (𝛼 𝛽⁄ = 2) or 75Gy4 
(𝛼 𝛽⁄ = 4). 
Based on experimental and theoretical considerations, this model is mechanically plausible for 
designing protocols in the dose range up to 10Gy / fraction, and, based on animal data, it is 
reasonable up to 15 to 18Gy per fraction (12). 
For a total dose of 34Gy to the spinal cord, it is estimated that after 1 year recovery is 76%. For a 
total dose of 38Gy it is estimated that after 2 years, a recovery of 85% occurs (2). 
Initial dose influences different time intervals from tissue tolerance to re-irradiation as well as 
conditioning the recovery of radiation damage in the first treatment. It is possible to administer a 
higher dose in the re-irradiation if smaller doses were used at the first treatment and if the intervals 
between treatments were longer (3, 13).  
When assessing tumor re-irradiation, it is necessary to consider whether the dose of tolerance of 
an organ has already been reached in the first course of treatment. Treating an area that had prior 
radiation is far more complex than the initial treatment. 
Key re-irradiation parameters evaluated in the decision process include (13, 14): 
▪ Data from previous treatment such as irradiated spinal cord volume and region; 
▪ Total dose; 
▪ Dose per fraction administered; 
▪ Time elapsed since the first treatment. 
Time interval between fractions / total treatment time 
Re-treatment in periods shorter than two years may increase the risk of developing complications, 
since lesions are more likely to develop during this time period (5). Nevertheless, when the time 
interval between the first treatment and the re-treatment is less than 6 months; the biologically 
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effective dose of each treatment is less of 98Gy2, no cases of radiation myelopathy where observed 
when cumulative BED is ≤120Gy2 (10). 
Experimental evidence from literature corroborates that the capacity of recovery spinal cord 
recovery depends on the time interval between the two treatments. Although there is evidence 
supporting the recovery of the spinal cord, there are still some controversies in the translation of 
experimental animal data to clinical situations.  
In schemes with multiple daily fractions it is essential to create an interval between fractions as 
long as possible. Due to the catastrophic effect of radiogenic myelopathy repair of sublethal 
damage in the spinal cord may not be complete after an 8 hour interval (3). Repair kinetics of the 
spinal cord is slower, so it is not advantageous to use schemes with time intervals of less than one 
day. 
Significant recovery of long-term damage occurs in rat spinal cord (13). Organ tolerance to re-
irradiation is influenced by the level of initial damage and time of onset of myelopathy (latency 
time). Thus, increasing time interval between treatments results in greater recovery and, 
consequently to lower doses delivered in re-treatment (2, 3, 13). 
Time of recovery from damage depends on the tissue or species, as well as on the age of the 
individual: In animal experiments performed it was observed that 3-week-old mice showed effects 
faster than adult mice. However, long-term recovery occurred more rapidly in younger rats (3 
weeks old) (2, 3). 
Long-term recovery was observed after 8 weeks and it increased with time interval to re-
treatment. The initial dose influenced tolerance to re-treatment and radiation damage repair at 
different intervals with long-term recovery after 6 months being approximately 45% (3, 13). 
Pathophisiology  
Radiation injury to the spinal cord is among the most studied experimental models of radiation 
injury and probably is the most fully documented clinical radiation complication. 
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To the thoracic cord, it is still apparent that its sensitivity to radiation is substantially less than 
that of the cervical cord. A significant oxygen effect exists, and it is possible that the thoracic cord 
is intrinsically less well oxygenated. Extrinsic conditions, such as smoking history or effects of 
lung cancer may result in the patients with thoracic irradiation having less well oxygenated 
nervous tissues. Haemoglobin levels are significantly greater in thoracic patients with myelopathy 
that in those without myelopathy treated to the same dose (15). 
The incidence of cervical myelopathy at 45Gy is, approximately, 0.03% and at 50Gy is, 
approximately 0.2%. Large lengths of cord, concomitant chemotherapy and other factors may 
increase this incidence (15). 
Spinal cord, besides being one of the most dose-limiting organs in radiotherapy, is also a risk 
organ present in several neoplasms. It is a serial architectural organ, being very sensitive to 
radiation in small portions of its extension. There is a possibility that the sensitivity of the spinal 
cord depends on the organization and structural distribution of its functional subunits (FSU), since 
there are structural differences between the different spinal segments. These differences are 
mainly patented in grey and white matter (16, 17). 
The effects arising from the volume of irradiated bone marrow may be related to vascular supply, 
collateral circulation and/or the ability to re-establish damaged vasculature through 
revascularization. There is also the issue of the release of cytokines and mediators of 
inflammation. Their release may be affected by the irradiated volume because the larger the 
volume the greater the release of these potentially harmful substances (5). 
In summary, recovery from initial damage is well established. The amount of recovery seems to 
be influenced by different factors, with initial damage expressed as a percentage of cord tolerance 
being the most important one. Time interval between the first treatment and re-treatment is also 
important as it is estimated than % recovery. 
The real total tolerance of the spinal cord may be about 130% if the tolerance dose for the first 
treatment as estimated by Kogel (18). Although the general phenomenon of repair occurs in humans 
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caution is necessary when translating experimental animal data to the clinical setting because of 
the life span, latency and dose response difference (19):  
▪ Histological pattern of myelopathy in animals differs from those found in humans; 
▪ Repair kinetics is probably different, and the time to achieve maximal repair and re-
tolerance in humans (18). It is of extreme interest to consider the knowledge about the 
kinetics of the evolution of the hidden damages caused by the previous treatment. 
In general, a higher re-treatment dose can be given following lower initial doses and longer 
intervals between treatments. From the sparse clinical and primate data, it appears that at least 
50% recovery from 45Gy would be obtained 2 years after treatment.  
Spine Stereotactic Body Radiation Therapy (SBRT) 
Spine SBRT, also known as spine stereotactic radiosurgery (SRS), is an emerging treatment 
option for patients with spinal bone metastases with or without a soft tissue component and is 
rapidly being adopted in the clinical although with limited high-quality evidence (1, 20).  
SBRT is a highly effective treatment able to deliver ablative doses to tumors with minimal doses 
to the surrounding normal tissues. It Is defined as radiotherapy treatment of tumors outside the 
brain with 1 to 5 dose fractions. It has been made possible in recent years due to advances in 
image guidance, target visualization and radiation delivery methods that allow large doses 
delivered to the target while sparing critical organs at risk (OARs). 
Outstanding results already have led to the suggestion that high doses per fraction may have 
greater efficacy than conventional fractionated radiation therapy (21). Local control rates in spine 
re-irradiation with SBRT reported in the literature range from 66% to 92% at 1 year (22). 
Initially, this technique was used to successfully palliate spinal metastases, even for tumors of 
radio-resistant histologies. This success with spinal metastases has led to the widespread 
extrapolation of SRS to the treatment of primary spine tumors and for benign tumors of the spinal 
cord (1, 23). 
SBRT has specific characteristics that differentiate it from conventional RT (24, 25): 
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▪ Treatment scheme, where dose delivery is performed in one or a few fractions, resulting 
in a high BED value. In several studies, we can verify that a re-irradiation performed with 
a SBRT treatment has higher BED values when compared to the first conventional 
radiotherapy treatment (Table 1). 
▪ Small irradiated volumes;  
▪ Inhomogeneous dose distribution (the inherent sensitivity of the dose distribution 
secondary to the steep dose gradient beyond the target volume); 
▪ Short treatment time (in a conventional treatment since the duration of the treatment 
would last for several months). 
In the limits defined by Emami (4, 6) all prescriptions were in 1.8 or 2Gy fractions. In contrast, 
SBRT prescription schemes typically range from 5Gy per fraction up to 20Gy per fraction or 
more. In this new radiation delivery paradigm, normal organ dose tolerance limits and the dose‐
volume response of the tumors depend strongly on the number of fractions used and the dose per 
fraction. 
After more than 20 years of Radiation Therapy Oncology Group (RTOG) trials, conventional 
radiation therapy had progressed to the point where it is possible to define dose tolerance limits 
in terms of 5% or 50% chance of a specified adverse event occurring within five years. In contrast, 
published follow‐up data for SBRT is inadequate to reliably determine the probability of adverse 
events (29). 
Radiation myelopathy is a rare late toxicity effect in the modern era of 3-dimensional conformal 
conventionally fractionated RT. This devastating late effect has re-emerged as a direct result of 
SBRT practice, where high-dose radiation is delivered adjacent to the spinal cord to be spared. 
Possible reasons include (30): 
i. Lack of understanding of tolerance to the spinal cord with high dose per fraction radiation 
therapy; 
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ii. Sensitivity of the spinal cord in SBRT dose distribution to small intrafraction motions 
where even 1- to 2mm shifts during treatment can increase the actual spinal cord dose 
delivered; 
iii. An assumption that a small point volume within the spinal cord can tolerate a higher dose 
of radiation than would traditionally be considered safe. 
Radiobiology: impact of repair, redistribution, repopulation, reoxygenation and 
radiosensitivity (5Rs)  
The classical fractionation principles, i.e., the Rs of radiobiology, explain the effects of high doses 
of ionizing radiation on tumors and adjacent normal tissues (Table 2). The outcome of standard 
clinical radiation treatment is determined by the Rs of radiobiology: 
Repair of sublethal DNA damage: normal cell are more effective than tumor cells in this process 
as observed from cell recovery in the 2 hour period after exposure to ionizing radiation. Radiation 
randomly interacts with molecules in the cell, but DNA is the main target molecule for the 
biological effects of radiation, including cell killing, carcinogenesis and mutation. In radiotherapy 
radiation damage is primarily manifested by the loss of reproductive capacity. Radiation causes a 
wide range of lesions in DNA such as single (SSB) and double-strand breaks (DSB) in the sugar-
phosphate backbone of the DNA molecule. SSB can be readily repaired using the undamaged 
chromatid as a template. The most deleterious lesion induced by ionizing radiation is DSB, a 
break in both strands of 10 base pairs or less. There are several mechanisms to repair DSBs, which 
indicate the importance and difficulty of repairing this type of DNA injury. The most important 
are non-homologous end joining (NHEJ) and homologous recombination (HR). Homologous 
recombination provides greater repair accuracy than NHEJ, the major pathway to repair DSB 
throughout all the phases of the cell cycle (34). 
Redistribution: when radiotherapy is given to a heterogenous cell population, cells may be in 
different phases of the cell cycle. Cells in S phase are more radioresistant and cells in late G2 and 
M phases are more sensitive. A small dose of radiation will destroy the more sensitive cells, and 
a resistant cell population that is now synchronized survives.  As fractionated radiotherapy 
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treatment continues, the resistant surviving cells will continue throughout the cell cycle and when 
a new dose is delivered some of these cells have moved from a resistant to a more sensitive stage 
and will then be killed more easily (35). 
Repopulation: Some time after irradiation an increase in cell division is seen in normal and 
malignant cells. Repopulation occurs at different rates depending on the tissues and represents 
cell proliferation that aims at compensating the cell population that was killed.  
This homeostatic response to cell loss occurs in situations other than irradiation and is related to 
specific cell-cycle time: as a result of radiotherapy cell death occurs after irradiated cells attempt 
mitosis and thus highly proliferative tissues (and tumors) show damage much faster than slowly 
proliferative tissues. 
Reoxigenation:  The level of oxygenation in a tumor is a major determinant of the effectiveness 
of radiotherapy. Tumor cell microenvironment presents areas with decreased pH, lack of nutrients 
and hypoxia. Oxygen concentration (pO2) varies between 10- and 80-mm Hg in normal tissues 
but in tumors these values can be lower than 5 mm Hg in some areas. This anomaly is due to the 
development of abnormal vasculature during tumor angiogenesis.  A significant proportion of 
tumor cells is hypoxic, showing great heterogeneity that is not correlated with standard prognostic 
factors such as size, stage and histological type (36). 
Hypoxia may have a crucial role in treatment outcome and may also influence metastatic capacity 
of tumor cells resulting from genetic changes such as those involving blood oxygen transport or 
inducing vascularization. As a result of prolonged exposure to hypoxia, cells can acquire genetic 
resistance to apoptosis suggesting that hypoxia can favour tumor progression through clonal 
selection of cells with more aggressive phenotypes (37).   
After an initial dose of radiotherapy, the more sensitive oxygenated cells are killed; during 
reoxygenation, surviving tumor hypoxic cells can increase their oxygen supply thus increasing 
their sensitivity to radiation. Biological efficacy of ionizing radiation relies on oxygen interacting 
with cells and making DNA lesions permanent (38). 
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Thus, tumor hypoxia may actually be a more serious problem with SBRT due to a reduction in 
reoxygenation between fractions as associated with small number of SBRT fractions (1 to 5).in 
comparison with conventional RT. This problem could be overcome if the next fraction of SBRT 
could be to delivered after tumor reoxygenation. And although there are no standard intervals 
between the high doses of SBRT, good clinical results were obtained in spite of different 
fractionation intervals (39). 
 Dividing total dose in several fractions saves normal tissue due to sublethal damage repair and 
cell repopulation occurring between treatment fractions. At the same time fractionation allows 
greater damage to the tumor as a result of reoxygenation of hypoxic cells as well as redistribution 
of cells into more radiosensitive stages of the cell cycle. Therefore, DNA repair and cell 
repopulation mechanisms induce normal tissues to become more resistant to a following dose of 
radiation; the other Rs, namely redistribution and reoxygenation have the opposite effect 
increasing radiosensitivity of tumor cells. The Rs represent the factors that modify tissue response 
to fractionated radiotherapy - overall radiosensitivity of a specific tumor depends upon a 5th R: 
Radiosensitivity (40), that translates the outcome of all the other Rs and represents individual 
sensitivity to radiation. These five fundamental factors represent the biological basis of 
radiotherapy. 
Some radiobiological questions remain without response regarding the evaluation of the doses 
administered in the SBRT and the effect of high doses per fraction. While in conventional 
radiotherapy the treatment time is approximately 5 minutes, in the SBRT the treatment session 
takes most longer (15-40 minutes).  
The major question raised when applying these radiobiological principles to SBRT is whether the 
fractionated dose of radiation administered in daily intervals is equivalent to the few large doses 
administered without breaks (as repair of sublethal damage occurs within the time interval 
between the administration of two doses of radiation in conventional fractionation) (32, 41).  
91 
 
As SBRT uses doses per fraction much higher than conventional radiotherapy, the radiobiological 
mechanisms underlying radiation response have been subject to controversy, regarding their 
application to extreme hypofractionation (41). Hypofractionation does not follow the basic 
principles of radiobiology to explain tumor responses obtained by conventional fractionation 
schemes. Thus, the relevance of the Rs of radiobiology in a scenario of hypofractionation is 
controversial: As the treatment time decreases, repopulation will be of lesser importance and the 
clinical significance of cell redistribution in the cell cycle, in a scenario of hypofractionation, is 
unclear. The advantages and disadvantages of the radiobiological mechanisms are presented in 
table 3. 
In spite of the controversy around the relevance of the 5Rs in SBRT, (32 ,42), it is now clear that 
these radiobiological concepts are sufficient to explain the impressive results obtained from 
clinical studies are the result of much larger biologically effective doses delivered (43). 
Table 4 presents information regarding 1st treatment and re-irradiation data from several studies. 
Also included are values regarding: 
▪ Total dose and the number of fractions delivered, both in the initial treatment and in the 
re-treatment; 
▪ Time elapsed between the end of the first treatment and the re-treatment; 
▪ 𝛼 𝛽⁄   ratio; 
▪ Treatment area (cervical, thoracic, lumbar and sacral); 
▪ Follow-up time; 
▪ Time until radiation myelopathy appears, should it occur. 
Based on the classification developed by Nieder et al., (10) (Table 4): when the interval between 
the two treatment courses is not shorter than 6 months and the dose of each course is BED ≤98Gy2, 
the cumulative BED where no case of radiation myelopathy (RM) has been reported is 120Gy2; 
for values between 120 and 135 Gy2, the risk of RM is small. 
Analyzing table 5 it is possible to highlight the following: 
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▪ Data presented by Wong et al., (44): patient received 20.6Gy in the 1st treatment in 6 
fractions and was retreated after 4 months. 
BED for 2nd treatment was 102.65Gy2; cumulative BED was 158.58Gy2. His risk score 
was 4, wich presented an intermediate risk of developing myelopathy, which occurred 
after 6 months; 
 
▪ Data presented by Schiff et al., (45), Grosu et al., (26), Nieder et al., (10) and Maranzano et 
al., (47): the cases reported had a time interval between treatments of more than 6 months, 
BED is ≤ 98Gy2 for each treatment, cumulative BED=120Gy2 and no cases of 
myelopathy; 
 
▪ Data presented by Sahgal et al., (28): patient had a time interval between treatments of 5 
months; cumulative BED=204.4Gy2 and a high risk of developing myelopathy (score of 
9). The follow-up time was very short (4 months) for the manifestation of symptoms, 
should they occur.  
 
▪ Data presented by Sahgal et al., (30): 9 cases of patients developing myelopathy were 
reported. BED values ranged from 181.3 to 337.5 for the re-treatment. Time to 
manifestation of symptoms in this group of patients ranged from 3 to 15 months. 
 
Limitations and constraints  
Most studies related to re-irradiation are based on data from retrospective studies or small 
prospective studies. In addition to this, reirradiated populations are more heterogeneous than 
patients with local or regional recurrence or second tumors (48). 
The major paradigm associated with spinal cord re-irradiation is related to the lack of evidence 
regarding repair of long-term damage in this organ. There is a greater uncertainty related to 
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tolerance rates during re-irradiation, since most of the existing data are derived from results 
obtained with animals, revealing long-term damage recovery (13). 
As SBRT is increasingly being employed in the treatment of spinal lesions, and although reports 
of toxicity are rare, the follow-up time is short and patient numbers are still small. The effect of 
concurrent chemotherapy is essentially unknown and needs to be investigated.  
The consensus is that SBRT is appropriate in the postoperative cases in patients with limited 
disease, radioresistant tumors and as another treatment strategy after failure of conventional 
radiotherapy treatment. 
The optimal dose prescription for SBRT remains controversial. On the one hand, a single fraction 
treatment results in better local control rates than obtained with conventional RT. This may be the 
result of larger biologically effective doses delivered with SBRT. Alternatively, higher rates of 
local control following single fraction treatment in retrospective series may simply reflect better 
outcomes in patients with less aggressive disease (49). 
 
Table 22 Variation in BED value according to treatment schedule. 
 Initial treatment Re-irradiation treatment 
Author α/β value 
Dose fx(Gy)/no 
fx 
BED 
Dose fx(Gy)/no 
fx 
BED 
Grosu et al., (26) 2 
1.25/32 65.0 1.8/16 55.1 
1.4/20 49.4 3.0/10 75.0 
Wright et al., (27) 
4 3.0/10 53.0 6/5 26.0 
4 3.0/15 79.0 6/5 15.0 
2 3.0/11 83.0 6/5 20.0 
Sahgal et al., (29) 2 
1.8/30 102.6 8.0/3 120.0 
0.9/28 36.5 10.5/2 131.3 
2.88/15 105.4 16.0/1 144.0 
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Table 23 Impact of radiobiological mechanisms in SBRT treatment. 
Biological 
mechanisms 
Description 
Repair of 
sublethal damage 
Treatment with SBRT has a longer irradiation time when compared to conventional radiotherapy. With this 
treatment, repair of sub-lethal damage may occur during prolonged exposure to radiation. After 30 minutes, 
the sublethal damage repair is greater than >10% (31. 32). 
Repopulation of 
cells after 
radiation 
Repopulation occurs depending on the type of tissue and the dose of radiation administered. In conventional 
radiotherapy, tumor cell repopulation occurs within 2 to 3 weeks after start of RT. Thus, it is possible that 
the repopulation of tumor cells may occur earlier in the treatment of SBRT or SRS than in conventional RT 
(32). Delivering a higher dose should mitigate any clonal expansion and thus offer a significant advantage to 
rapidly dividing tumors (33). As treatment time of SBRT lasts is short, 2 weeks at most, repopulation of tumor 
cells will not be a problem (31). 
Redistribution of 
cells within the 
cell cycle 
Reducing the number of fractions alters the probability of irradiating a cohort of cells as they move into a 
radiosensitive phase (33). 
After irradiation with a single fraction of 15–20Gy, cells are indefinitely arrested in the phases of cell cycle 
where they were irradiated and undergo interphase death (31). After irradiating the cell cycle with a dose of 
20Gy in a single exposure, cell cycle progression was delayed, and many cells underwent necrosis in the 
phases of the cycle where they were irradiated. The cells that were irradiated slowly progressed to the G2 
phase and died (32). 
Reoxygenation of 
the surviving cells 
In SBRT, due to the vascular damage caused by the high doses of radiation, the intratumoral environment 
becomes hypoxic. Hypoxic cells reoxygenated when irradiated with a relatively low dose per fraction, i.e., 
less than 10Gy (31). Following administration of a SBRT or SRS treatment, massive vascular destruction of 
the tumor occurs, and reoxygenation of hypoxic cells occurs 2-3 days after irradiation. As oxygen 
consumption declined dramatically after massive death of tumor cells, surviving hypoxic cells can be 
reoxygenated. Changes in the oxygenation status of the tumors after irradiation with high doses are still 
unclear (32). SBRT has a theoretical disadvantage because of the short delivery time. Although this might be 
compensated by the high doses per fraction. 
Radiosensitivity 
SBRT attenuates differences in tumor death that are directly attributable to variations in radiation sensitivity 
of individual tumor cells. Large doses per fraction and short treatment time used in SBRT provides less 
opportunity for the development of resistant stem cells (33). 
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Table 24 Advantages and disadvantages of radiobiological mechanisms Adapted from (33):  
Radiobiological 
mechanisms 
Advantage Disadvantage 
Repair 
Improvements in the technique of dose delivery 
allows dose reduction delivered to adjacent normal 
tissues. 
Limitation of the number of cycles of damage and 
repair that separate the tumor response from normal 
tissue toxicity. 
Repopulation 
Tumor repopulation is greatly reduced or eliminated 
during a treatment with less fractions. It is 
specifically relevant for radiation-resistant tumor 
stem cells. 
None 
Redistribution 
The distribution of the cells will be affected by the reduced number of fractions. The clinical significance is 
still unknown, so it is not possible to enumerate the advantages and disadvantages of this biological 
mechanism. 
Reoxygenation None 
A smaller number of fractions potentially reduces 
reoxygenation between fractions, which results in 
an increase in radioresistance. 
Radiosensitivity 
A single fraction dose greater than 10Gy may trigger 
apoptosis of endothelial cells. 
Normal late-reacting tissues are more 
radiosensitive at higher doses per fraction and so 
the risk of late complications is higher at higher 
doses per fraction (25). 
 
 
 
Table 4 Risk of developing myelopathy from the characteristics mentioned in the table. Adapted from (10). 
Points Cumulative BED in Gy2 with interval < 6 months and a BED of 1 
course ≥102 Gy2 
Risk of developing 
myelopathy 
0 ≤ 120.0 
Low risk 
(≤3 points) 
1 120.1 – 130.0 
2 130.1 – 140.0 
3 140.1 – 150.0 
4 150.1 – 160.0 x (4.5) x (4.5) 
Intermediate risk 
(4-6 points) 
5 160.1 – 170.0 
6 170.1 – 180.0 
7 180.1 – 190.0 
High risk 
(>6 points) 
8 190.1 – 200.0 
9 > 200.0 
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 1st treatment  Re-irradiation  
Author Sample Total dose 
(Gy) 
Dose fx(Gy)/no 
fx 
Interval 
(months) 
Total dose 
(Gy) 
Dose 
fx(Gy)/no fx 
Nivel 
treated 
Value of 
α/β (Gy) 
Initial 
BED 
Irradiation 
BED 
Total BED 
Follow-up 
(months) 
Time to 
myelopathy 
(months) 
Wong et 
al., (44) 
11 
2.0+45.9 2.0/1+3.06/15 12 23.6 2.36/10 T 
2 
120.13 51.45 171.58 
≥60 
4 
23.5+18.2 2.35/10+3.64/5 19 13.6 2.72/5 T 102.44 32.096 134.54 16 
20.6 3.43/6 4 36.4 3.64/10 T 55.93 102.65 158.58 6 
20.1 1.26/16 48 
14.3+3.2 
+22.6+2.57 
2.38/6+1.6/2+ 
3.76/6+2.57/1 
T 33.25 108.04 141.29 11 
16.0 3.2/5 57 22.0 7.33/3 T 41.60 102.63 144.23 7 
24.0+24.0 3.0/8+1.5/16 45 18.1 1.81/10 T 102.00 34.48 136.48 13 
20.4+20.3 4.08/5+4.06/5 10 8.2 8.2/1 T 123.53 41.82 165.35 4 
24.4 4.88/5 2 17.0 3.4/5 T 83.94 45.9 129.84 14 
31.2 1.56/20 71 30.3 5.05/6 C 55.54 106.81 162.35 25 
33.9 3.39/10 2 25.6 2.56/10 T 91.36 58.9 150.4 13 
50.0 2.5/20 27 10.4 1.04/10 T 112.50 15.81 128.31 11 
Schiff et 
al., (45) 
54 
30.0 3.0/10 Median 9.1 
(range: 1-
51.3) 
30.6 1.8/17 T 
3 
60.0 48.96 108.96 
4.2 No cases 30.0 3.3/9 39.6 1.8/22 L 63.0 63.36 126.36 
30.0 3.0/10 22.0 2.0/11 C/T 60.0 36.7 96.7 
Sminia et 
al., (46) 
8 
16.0 8.0/2 52 
12 
4 
61 
30 
20 
150 
73 
20.0 4.0/5 T 
2 
80.0 60.0 140.0 
1-54 No cases 
39.0 3.0/13 21.0 3.0/7 T 97.5 52.2 149.7 
8.0 8.0/1 18.0 3.0/6 C 40.0 45.0 125.0 
49.6 1.6/31 50.0 2.0/25 L 69.4 75.0 144.4 
37.4 2.2/17 21.0 3.0/7 T 78.5 52.2 130.7 
24.0 3.0/8 21.0 3.0/7 T 60.0 52.2 164.4 
25.0 1.7/15 16.0 4.0/4 T 46.0 48.0 142.0 
35.25 1.5/23.5 30.0 3.0/10 L 48.5 52.5 125.0 
Grosu et 
al., (26) 
8 
40.0 1.25/32 
Median 30 
(range: 6-
63) 
29.0 1.8/16 T 
2 
65.0 55.1 120.1 
Median 16 
(range: 5-
44) 
No cases 
30.0 3.0/10 30.0 2.0/15 L 75.0 60.0 135.0 
40.0 2.5/16 30.6 1.8/17 T/L 90.0 58.1 148.1 
40.0 2.0/20 30.6 1.8/17 T 80.0 58.1 138.1 
50.0 2.0/25 18.0 3.0/6 T 100.0 45.0 145.0 
30.0 3.0/10 30.0 2.0/15 T 75.0 60.0 135.0 
29.0 1.4/20 30.0 3.0/10 T 49.4 75.0 124.4 
36.0 3.0/12 30.0 2.0/15 L 90.0 60.0 150.0 
Wright. et 
al., (27) 
37 
40.0 2.67/15 
Median 19 
(2-125) 
20.0 4.0/5 SC 2 93.0 11.0 104.0 
8 
(range 1-
51) 
No cases 
30.0 3.0/10 20.0 4.0/5 CE 4 53.0 4.0 57.0 
30.0 3.0/10 20.0 4.0/5 SC 2 75.0 17.0 92.0 
50.4 1.8/28 20.0 4.0/5 CE 4 73.0 9.0 82.0 
37.7 2.51/15 20.0 4.0/5 SC 2 85.0 20.0 105.0 
T, thoracic; C, cervical; L, lumbar; SC, spinal cord; CE, cauda equina.  BED is calculated using the formula: 𝐵𝐸𝐷 = 𝑛 × 𝑑 × [1 + 𝑑 (𝛼 𝛽⁄ )]. 
Table 5 Summary of published reports of treatments performed using re-irradiation. 
97 
 
T, thoracic; C, cervical; L, lumbar; S, sacral; SC, spinal cord.  BED is calculated using the formula: 𝐵𝐸𝐷 = 𝑛 × 𝑑 × [1 + 𝑑 (𝛼 𝛽⁄ )]. NR, not reported. 
 1st treatment   Re-irradiation  
Author Sample 
Total 
dose 
(Gy) 
Dose 
fx(Gy)/no fx 
 
Interval 
(months) 
Total dose 
(Gy) 
Dose 
fx(Gy)/no fx 
Nivel 
treated 
Value of 
α/β (Gy) 
Initial 
BED 
Irradiation 
BED 
Total 
BED 
Follow-up 
(months) 
Time to 
myelopathy 
(months) 
Nieder et 
al., (10) 
7 
60.0 2.0/30  37 64.0 2.0/32 C-T 2 37.5 70.0 107.5 7 
No cases 
60.0 2.0/30  31 56.0 2.0/28 C 2 37.5 67.0 104.5 5 
70.0 
15 x 2 Gy 
followed by 
twice-daily 
radiotherapy 
with 1.8 Gy in 
the morning and 
1.5 Gy in the 
afternoon 
 
23 50.0+12.0 2.0/25+3.0/4 C 2 80.0 43.0 123.0 10 
59.4 1.8/33  12 45.0 1.8/25 C 2 96.0 85.5 181.5 8 
36.0 3.0/12  30 30.0 2.0/15 L-S 4 63.0 39.0 102.0 20 
44.8 1.6/10+1.8/16  96 36.0 2.0/18 T 2 83.5 72.0 155.5 5 
40.0 2.5/16  26 30.0 2.0/15 L 4 65.0 45.0 110.0 17 
Maranzano 
et al., (47) 
12 
8.0 8.0/1  31 8.0 8.0/1 
SC 2 
40 40.0 80.0 
SI No cases 
8.0 8.0/1  9 16.0 2.0/8 40 80.0 120.0 
8.0 8.0/1  9 8.0 8.0/1 40 40.0 80.0 
8.0 8.0/1  5 8.0 8.0/1 40 40.0 80.0 
8.0 8.0/1  2 8.0 8.0/1 40 40.0 80.0 
8.0 8.0/1  4 20.0 5.0/4 40 60.0 120.0 
Sahgal et 
al., (28) 
19 
37.5 2.5/15  5 24.0 8.0/3 C 
2 
 
84.4 120 204.4 4 
No cases 
39.1 2.3/17  39 25.0 5.0/5 L 84.1 87.5 171.6 7 
30.0 3.0/10  6 24.0 6.0/4 L 75 96 171 5 
50.0 2.0/25  11 24.0 8.0/3 T 100 120 220 8 
40.0 1.82/22  81 20.0 10.0/2 T 76.4 120 196.4 55 6 
25.2 0.9/28  70 21.0 10.5/2 T 36.5 131.3 167.8 29 5 
21.2 4.24/5  11 14.0 14.0/1 T 66.1 112 178.1 17 3 
51.9 1.85/28  18 33.0 11.0/3 C 99.9 214.5 314.4 11 8 
43.2 2.88/15  12 16.0 16.0/1 T 105.4 144 249.4 3 3 
Sahgal et 
al., (30) 
66 
    25.0 12.5/2 T   181.3  17 9 
    24.0 8.0/3 C-T   120  9 9 
  
 
 16.0 16.0/1 
Clivus-
C1 
  144  24 13 
 NR   25.0 25.0/1 C NR  337.5 NR 40 13 
    25.0 25.0/1 C   337.5  39 5 
    18.0 18.0/1 T   180  24 12 
    16.0 16.0/1 C   144  8 3 
    14.0 14.0/1 T   112  16 6 
    30.0+14.0 3.0/10+14.0/1 C   187  23 15 
Table 5 (cont.) Summary of published reports of treatments performed using re-irradiation. 
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